Wallace L. Akerley,
MD
Languages Spoken: English
Wallace Akerley, MD
Professor, Department of Medicine, Division of Medical Oncology
Huntsman Cancer Institute
Wallace Akerley, MD, is a professor in the Department of Medicine, Division of Medical Oncology at the University of Utah School of Medicine, co-director of the Thoracic Cancer Program at Huntsman Cancer Institute (HCI), and member of the Experimental Therapeutics Program.
Improvements in cancer treatment evolve from laboratory discoveries, animal studies, and controlled clinical trials. This process is most effective when basic scientists and clinicians work side by side. Huntsman Cancer Institute offers a unique opportunity for basic scientists and clinicians to collaborate in solving problems related to cancer patients. Clinical trials offer promising new treatments to qualifying patients and are a critical step in developing improved cancer treatments.
In addition to his leadership responsibilities, Akerley treats patients with many types of cancer, focusing on lung cancer and melanoma. He participates on the lung cancer committees of two national organizations for cancer treatment: Southwest Oncology Group (SWOG) and National Comprehensive Cancer Network (NCCN). Akerley joined Huntsman Cancer Institute in 2002. Previously, he was director of medical oncology and associate director of the Boston University Cancer Center. He received his medical degree at Brown University in Rhode Island, completed his residency at the University of Southern California (USC), and served additional fellowships at USC/Norris Comprehensive Cancer Center and the Norris Cotton Cancer Center at Dartmouth College in New Hampshire.
Wallace Akerley, MD is a medical oncologist with greater than 30 years experience as a principal investigator on numerous clinical research trials who actively cares for patients with lung cancer and melanoma. With the need for improved cancer treatment, it is imperative to incorporate new treatments when possible. Many of the FDA approved agents were studies at HCI years before they were approved for every day use.
Clinical Locations
Clinic 1A, Thoracic
801-213-4266
Specialties
Board Certification and Academic Information
| Academic Departments | Internal Medicine
-
Professor |
| Academic Divisions | Oncology |
| Board Certification | American Board of Internal Medicine (Sub: Hematology) American Board of Internal Medicine (Sub: Medical Oncology) American Board of Internal Medicine (Internal Medicine) National Board of Medical Examiners |
| Cancer Center Programs | Experimental Therapeutics |
Patient Rating
The Patient Rating score is an average of all responses to care provider related questions on our nationally-recognized Press Ganey Patient Satisfaction Survey.
Responses are measured on a scale of 1 to 5 with 5 being the best score.
Likelihood of recommending care provider
4.9/ 5
Care provider spoke using clear language
4.8/ 5
Care provider's explanation of condition/problem
4.8/ 5
My confidence in care provider
4.9/ 5
Care provider's effort to include me in decisions
4.8/ 5
Wait time at clinic
4.0/ 5
Time care provider spent with me
4.7/ 5
Care provider's concern for questions & worries
4.8/ 5
Care provider's friendliness and courtesy
4.9/ 5
Patient Comments
Patient comments are gathered from our Press Ganey Patient Satisfaction Survery and displayed in their entirety. Patients are de-identified for confidentiality and patient privacy.
UofU Patient
June 01, 2019
Nothing to say here.
UofU Patient
May 30, 2019
Very easy to talk to. Friendly and personable. Professional
UofU Patient
May 20, 2019
excellent
UofU Patient
May 11, 2019
Dr. Akerley has the best bedside manner. He is kind and clear in his communication. He made me feel he was being honest and hopeful all at the same time.
UofU Patient
May 09, 2019
We really like Dr.Ackerly. He puts us at ease immediately and is very straightforward. Spends time just visiting as well as treating Jerry.
UofU Patient
April 30, 2019
Dr. Ackerley is accessible and sincere. He has explanations and statistics ready to answer questions and his suggestions for treatment are clear and concise.
UofU Patient
April 20, 2019
Best care ever!!
UofU Patient
April 20, 2019
no complaints
UofU Patient
April 11, 2019
I feel very fortunate to have the best doctors available. I have full confidence in the doctor's care for me.
UofU Patient
February 25, 2019
One area of improvement that I would recommend, is explaining test results more thoroughly. When I left I understood that I had a metastatic tumor, but not that it was wrapped around my carotid, juggler etc. which I think is important to know.
UofU Patient
February 25, 2019
I think Dr Akerley is terrific and caring and knowledgeable. But the wait times are ridiculous
UofU Patient
February 02, 2019
Dr. Akerly's "bedside manner" was welcomed. I liked him a lot.
UofU Patient
January 13, 2019
the whole team listens and explains all answers. I feel extremely confident with my doctor and team!
UofU Patient
December 10, 2018
They were very helpful in explaining my cancer to me to make sure that I understood my condition to make the best decisions concerning my health.
UofU Patient
December 09, 2018
could not ask for better i have never been to a medical place of any kind that treats people with suck kindness and respect thank you all
UofU Patient
November 30, 2018
very good
UofU Patient
November 11, 2018
all good.
UofU Patient
October 11, 2018
There are some who have been gifted with the talent from ABOVE and this Doctor is one of them....
UofU Patient
October 06, 2018
he acted on our concerns and agreed quickly to address them
UofU Patient
September 07, 2018
I would recommend to anyone who needed this care.
UofU Patient
August 22, 2018
very good
UofU Patient
August 21, 2018
very informative
UofU Patient
August 10, 2018
Couldn't ask for better care, excellent!
UofU Patient
July 05, 2018
I love Dr. Akerley, but this time he said they see something, but did not go into detail about what it was. He said it is significant enough for a follow-up with x-rays and blood work, but I have to wait 3 months. This is an awfully long time to wait and wonder what is going on. I really would like to be seen sooner.
UofU Patient
June 06, 2018
Dr Akerley seemed very disinterested in seeing me as a patient or trying to help me. His explanation of my conditions were very Elementary & nothing that I didn't already know. His "Fellowship" Doctor that actually spent time with me & examining me was very caring & seemed very willing to look into further testing & options for treatment.
UofU Patient
May 11, 2018
I usually have to wait to see Dr. Akerley, but he is worth the wait!! I understand that he deals with so many complex issues and patients that it is completely understandable that he gets behind. He never makes you feel bad or silly, for having anxiety and voicing the same concerns over and over. He is a very caring and kind man and an excellent and experienced Doctor.
UofU Patient
May 02, 2018
very good
UofU Patient
April 15, 2018
Always a good experience with my care provider.
UofU Patient
April 07, 2018
very friendly and thorough
UofU Patient
March 12, 2018
We trust all medical advice we receive from both U of U and Huntsman. To be able to have that amount of trust in any institution is rare.
UofU Patient
March 07, 2018
Dr. Akerley and his staff are wonderful. I would recommend any and all of them to others.
UofU Patient
February 16, 2018
It is so nice to talk to one of the care providers and feel like they care about you. They always make sure that you understand everything before you leave the clinic.
UofU Patient
February 03, 2018
good
UofU Patient
February 01, 2018
I entered fair for the ampunt of tiume spent simply because it was a quick visit. I'm improving, so there just wasn't much to discuss.
UofU Patient
January 20, 2018
I have recommended the doctor to a colleague at work recently diagnosed with the same cancer as mine.
UofU Patient
January 15, 2018
My concern again is that the team seems to be very rushed and things are being missed. There is not enough time to really understand symptoms rather than quick review of pictures. I believe we have missed several things in my care because symptoms have been dismissed. My care provider and I eventually been proven correct on several occasions and have had to endure in our opinion unnecessary teams. We are concerned that the attention to detail and high level of care are now being compromised by outside business factors. We are leaving most often with more questions and wondering rather than a knowledge and understanding of what to expect. We asked my primary care physician to follow up on my behalf and she has yet to receive any response from the team to her questions.
UofU Patient
November 25, 2017
Dr. Akerley is the best!
UofU Patient
November 20, 2017
Always good experience with Dr. Akerley and others.
UofU Patient
August 28, 2017
They were running so late that I just saw the PA and did not see the doctor.
UofU Patient
August 21, 2017
Because it was late in the day, I saw my primary care oncologist and an intern or fellow -- unsure. Both were very clear, but I was surprised I didn't see a NP or Nurse.
UofU Patient
August 18, 2017
great care and staff
UofU Patient
July 29, 2017
Everything was great. Love this hospital
UofU Patient
July 19, 2017
I really do like Dr. Akerley, he has been with me from the start and has healed me, I am 4 years out and he is happy with my results.
UofU Patient
July 17, 2017
Dr. Akerlley is a gem. He is caring and considerate and makes you feel you are his only concern.
UofU Patient
July 13, 2017
The only thing that was bad about this appointment was that Dr Akerly assumed I had been tested 6 months ago. He based treatment suggestions upon that fact. It became very distressing for me and my family members that were with me. It wasn't until my husband asked him if the fact that it had been almost 2 years made a difference. It did in fact make a difference and made the situation entirely more bearable. I know he was an hour behind schedule by time I got in, and I have been coming there since 2009, but the little minute it would have taken him to check my previous records could have alleviated a lot of stress and fear. However, that being said, Dr Akerly is an amazing doctor. I feel very lucky that I am under his care and I am grateful to him for all of his help on this lengthy and trying journey.
UofU Patient
June 13, 2017
he is the best dr ever
UofU Patient
June 05, 2017
I quite often tell others how impressed we are with the outstanding care I have recieved from Dr Akerley, his Assistants and the whole clinic at Huntsman.
UofU Patient
June 03, 2017
Dr Akerley listens which is rare with specialists. Wonderful man
UofU Patient
May 18, 2017
It seems like a long wait to us. (15 min in exam room.)
UofU Patient
April 29, 2017
We like Dr. Akerley very much
UofU Patient
April 26, 2017
this apt was a waste of time
UofU Patient
April 14, 2017
best dr ever
UofU Patient
April 08, 2017
Dr. Akerley was patient, direct and kind and inspired complete confidence in his knowledge and ability. His staff also were excellent.
UofU Patient
February 18, 2017
I like Dr. Akerley and I feel he is very competent and thorough. He takes the time to explain things and to answer all my questions.
UofU Patient
February 01, 2017
it was enough time to have questions answered timely manner
UofU Patient
December 26, 2016
Recognizing that the doctor is a lung cancer specialist, is familiar with Mesothelioma but not a Mesothelioma specialist.
UofU Patient
December 09, 2016
great experience
UofU Patient
November 30, 2016
I trust Dr. Akerly and all that assist him.
UofU Patient
November 29, 2016
The education I received was worth the price of admission!!!
UofU Patient
November 01, 2016
I have always felt like the doctor and staff will take good care of me. They make me feel comfortable and explain things in detail.
UofU Patient
October 30, 2016
good
UofU Patient
October 17, 2016
spent a long time with me. very special doctor
UofU Patient
October 03, 2016
As I stated previously, and especially in the "explanation room" with Dr. Akerley, Julie and Terry, I (and my family members) were treated with respect, even though at that point, the news about my cancer was far from good.
UofU Patient
September 30, 2016
The usual excellent experience with NP Julie Luckart and Dr Akerley
UofU Patient
September 27, 2016
I have the utmost confidence in Dr. Akerely. I also appreciate how well he listens to my questions and concerns. He is patient, and seems to have time to answer all of my questions. I feel like he really cares about me and my experience as a cancer patient and person.
UofU Patient
September 11, 2016
dr. Akerley is a fabulous physician. I feel very confident in his care.
UofU Patient
September 04, 2016
Given the scenario a bit more time and an offer for any other form of support would have been welcome & appreciated
UofU Patient
September 02, 2016
dr Akerley took the time to call radiologist prior to entering exam room in response to my question to the ?fellow about prior CT reading
UofU Patient
August 11, 2016
It is always a good experience with Dr. Akerley.
UofU Patient
August 08, 2016
Dr Akerley spent a lot of time with me and answered a lot of questions I had. It made me feel good that the "Huntsman Center" agreed with Dr Frames treatment as it seems the Huntsman is the best. I was looking for a second opinion and am glad I came. I will probable stay with Dr Frame as he is much closer to where I live.
UofU Patient
August 08, 2016
Dr. Akerley is always straight forward with me and my family. Good or bad, he explains everything clearly and always leaves us feeling good about the next step.
UofU Patient
August 08, 2016
very good answered questions very good and informative
UofU Patient
July 28, 2016
Dr. Wallace Akerley always cares for his patients. His expertise gives us much confidence. We believe Huntsman is the best hospital because it has the best doctors. A BIG THANKS to Dr. Akerley and his awesome team!!!
UofU Patient
July 24, 2016
The number of people we met was overwhelming for a first visit for someone with brain issues.
UofU Patient
March 12, 2016
Dr. Akerley is great, so glad for all he has done! He is always very optimistic and gives us real hope. Very grateful for his excellent care and team!
UofU Patient
February 17, 2016
Very happy with our care provider. He is just awesome.
UofU Patient
February 10, 2016
All healthcare persons were very helpful. Dr. Akerly is fantastic!
UofU Patient
January 23, 2016
The provider was awesome.
UofU Patient
December 11, 2015
I have already told all of my supportive family and friends how wonderful my experience has been!
UofU Patient
December 03, 2015
It took a number of visits before I met the doctor that was in charge of the trial I am participating in. He was able to provide me with information that I needed about my cancer and the trial I am in.
UofU Patient
December 03, 2015
NP Julie Luckart was outstanding in the depth of information she provided, and Dr Akerley summed it all up reasonably and ordered what seem to be the needed tests
UofU Patient
November 02, 2015
We can't say enough good things about Dr. Akerly and his staff. It is rotten to need their care, but so very glad they are the ones taking care of us.
UofU Patient
October 11, 2015
They show a great deal of concern and treat us with dignity and respect. Such a wonderful group of medical professionals.
UofU Patient
October 06, 2015
Julie and Dr. Akerley spent a good amount of time with me. They feel more like family than doctors/nurses.
UofU Patient
August 26, 2015
good
UofU Patient
August 15, 2015
we are in awe
UofU Patient
August 05, 2015
extremely satisfied
UofU Patient
August 02, 2015
Dr. Acherly is great!
UofU Patient
July 29, 2015
Dr Akerley was very kind and straightforward. Use.d words we could understand and took his time
UofU Patient
July 22, 2015
Cancer visits with our doctor, Dr. Akerley, are a family affair for us, with each family member picking-up on different details of the good doctor's discussion of the treatment and state of health we are receiving. Words cannot express the gratitude we all feel for this doctor as we share together what we learned from each appointment.
UofU Patient
July 14, 2015
On a scale of 1 to 10, Dr Akerley is a 12 :) I am so glad I was lucky enough to get him as my doctor. He helps make a really nasty disease easier to live with and His and Terry's support are invaluable in these dire times.
UofU Patient
July 09, 2015
Dr Akerley is saving my life. I am alive today because of him.
UofU Patient
July 05, 2015
he spends the time needed to help you understand any tests or changes that influence decisions that must be made.
UofU Patient
June 27, 2015
very good team
UofU Patient
June 12, 2015
I know it was the second time to hear the information, but I came away with a much better understanding.
UofU Patient
June 10, 2015
If I didn't have a "sick" partner here in Las Vegas, I certainly would have treated at the Huntsman Center.
UofU Patient
May 22, 2015
dr ackerley is great and i really appreciate his advice.
UofU Patient
May 19, 2015
good
UofU Patient
May 11, 2015
I think based on my meeting with the doctor that he has preconceived opion about me. It was negative regarding any assistance for my care. Therefore, he did not examine me. Based on his examination and meeting with me, I did not need to come to Utah. The rest of the staff was very interactive, listened and supportive. Perhaps in future, he may want to inform the referring doctor that he would not be of any help. It would save the patient time, energy, money to make the trip.
UofU Patient
May 04, 2015
I kept him too long as I was trying to process what he was telling me, so that probably made him late for other appointments. He was so helpful and kind!
UofU Patient
April 08, 2015
I feel I have the best team I could ask for supporting me through this illness
UofU Patient
March 27, 2015
The Dr. spent good time with us, the NP is great. the PA was not good.
UofU Patient
March 09, 2015
Dr Akerley and his team helped me become at peace during this time while I LIVE with my cancer. I felt encouragement to make the best of each and every day. The LCSW is excellent at conveying compassion and understanding.
UofU Patient
March 09, 2015
Very little information on effects of Radiation after completion of last dose. No interview with anyone. This is critical in my opinion. I had no idea how fatiqued I would feel.
UofU Patient
February 23, 2015
Dr. Akerley didn't have all the information he should have been given so instructions or decisions will wait for a phone call from him.
UofU Patient
February 17, 2015
I would recommend Dr. Ackerley to others.
UofU Patient
February 14, 2015
I couldn't wish for a better experience
UofU Patient
February 07, 2015
great
UofU Patient
January 24, 2015
A1 clinic's staff is outstanding
UofU Patient
January 18, 2015
W are so impressed with Dr Akerley. He is obviousl knowledgeable, but he took the time needed with us, and made us feel like we were the most important thing at that time. His explanations were acccurate, and laced with compassiion, hope and mercy.
UofU Patient
January 13, 2015
completely reassured by my visits with Dr. Wally Akerley that issues have been attended to and that I am doing the best I can with my disease state.
UofU Patient
December 22, 2014
Julie and Dr. Akerley are a great team and I feel very fortunate to be in their care.
UofU Patient
December 18, 2014
There is NO bad bad experience with this oncology team. These people are are awsome, one could not wish for more or better, they make a really nasty disease much easier to deal with. I thank all three of them from the bottom of my heart
UofU Patient
December 16, 2014
Dr. Ackerley is very caring and kind as well as professional. I could not have asked for better care.
UofU Patient
November 24, 2014
Outstanding service provided by each of the care providers. I felt as if I was getting special care from everyone involved.
UofU Patient
October 08, 2014
I am always treated very well when I have to go.
UofU Patient
October 05, 2014
I would highly recommend Dr. Akerley to others, and have done so.
UofU Patient
September 14, 2014
Excellent
UofU Patient
September 08, 2014
Time was personally given to me, to help me fully understand my situation and future medical needs.
UofU Patient
July 20, 2014
I saw Dr. Akerley and Terry Van Duren during this visit. They are always thorough, friendly and answer all my questions or get the answers if they are not available. I give them our highest praise as well.
UofU Patient
July 17, 2014
The entire care provider staff is very thoughtful
UofU Patient
July 09, 2014
We were impressed by Dr Akerley's compassion and concern for me as a patient. He has a very healing professional style.
UofU Patient
July 04, 2014
I fill I was, and am, in the best of hands
UofU Patient
June 16, 2014
Dr Ackerley is the most competent Dr. I have ever had. His concerns for me as well as my family are amazing. I have so much confidence in him and his staff. He is a pleasure to work with
UofU Patient
June 15, 2014
Appreciate Dr. Ackerly's time he spends with us and his willingness to debate treatment options
UofU Patient
June 10, 2014
I would recommend Huntsman to everyone I talk to!!!!! Awesome place and staff!!!!!
UofU Patient
May 16, 2014
Julie spent a lot of time answering our questions with regards to medication side effects and the cancer itself. She also provided additional help in ensuring my fathers overall help. I am amazed at the teams ability to assess and treat the overall wellness especially the emotional and mental aspects. Dr Akerley and team are amazing every time we visit.
UofU Patient
April 26, 2014
The doctor was awesome!, likewise the assistants.
UofU Patient
April 16, 2014
Dr. Akerley, Terry and Julie are the best. As was Dr. Sharma and Cynthia when I was seeing them a couple of years ago during a study.
UofU Patient
March 28, 2014
We enjoyed the time Julie, NP spent with us. She was friendly, informative, filled with information. Dr. Akerley was just as friendly, informative, and filled with information. It was a lot of information to grasp. Maybe a break sometime along the way would have been a good idea.
UofU Patient
March 06, 2014
We appreciate Dr. Akerley, Julie, Terry for the one on one care they give to me the patient, and to my husband. They are very patient with my questions and going over any treatment plan.
UofU Patient
March 03, 2014
My dad was treated with such respect, kindness & compassion
UofU Patient
February 13, 2014
Amazing! And the time that Dr. Akerley spent with us was amazing!
UofU Patient
February 01, 2014
As with the assistant, the doctor could have abbreviated the explanations to fit the ability of the patient to understand. The doctor gave generously of his time, and the last few minutes helped more than everything prior as he responded to our questions.
UofU Patient
January 07, 2014
I put my entire care in their hands with confidence
UofU Patient
December 06, 2013
Dr Ackerly was extremely personable, professional, yet able to relate to me on a human level. I was able to follow him, without feeling inept. I would recommend HCI again. I am completely confident in their recommendations and would come to HCI anytime I had a need.
UofU Patient
November 25, 2013
I would highly recommend Dr. Akerley to anyone, as he is a very caring, thorough, and knowledgeable doctor and has been very helpful to me.
UofU Patient
September 23, 2013
Dr. Akerley is seriously a great person to have as a doctor (along with Julie and his staff). He shows the utmost respect and concern for me and my treatment. I highly recommend him. He always shows concern for me and the pains or side effects that I might have. He never brushes your concerns off and understands my needs and addresses them properly.
UofU Patient
September 04, 2013
Dr. Akerley was unfamiliar with my condition initially. My husband, who is a pulmonary, critical care physician, explained it and clarified it for him. This was due to the inadequate records provided to him. I was told that all the records were received prior to the appointment but they were not. He did not have the final pathology report and other records which would have helped him better know my case. I know that he later reviewed them and spoke with my oncologist here in Medford, OR. I liked him very much and he was very helpful. I feel like I am getting the best option of treatment with his input.
UofU Patient
August 21, 2013
The doctors and staff have been supper to me. I don't know what could be changed other than not being sick.
UofU Patient
August 19, 2013
Love Dr Akerley and have complete confidence in his recommendations
UofU Patient
August 07, 2013
I would recommend Huntsman to everyone one I have contact with, that need cancer care!
UofU Patient
August 05, 2013
Again, just an unbelievable experience. They did not make me feel less of a person due to this cancer. I heard a more complete explanation of what I have been going thru these past three years and what to expect in the future. Using the diagram helped immensley along with past/current scans and what they showed.
UofU Patient
July 16, 2013
You could not ask for better care.
UofU Patient
July 11, 2013
so much concern and understanding
UofU Patient
June 10, 2013
good
UofU Patient
May 28, 2013
Dr. Akerley is an exemplary physician with a wonderful sense of humor and understanding demeanor. He often has to put up with some teasing from me and sometimes irreverent humor of both myself and my husband.
UofU Patient
April 19, 2013
Everything was good
UofU Patient
March 25, 2013
good
UofU Patient
February 25, 2013
excellent
UofU Patient
February 21, 2013
My experiance has been nothing but positive.
UofU Patient
February 18, 2013
I already have reccommended U of U hosp. and Huntsman. They saved my life. What fabulous care!!
UofU Patient
February 05, 2013
Overall I felt they had my concerns in mind.
UofU Patient
February 04, 2013
Dr. Akerley and his staff are always kind and professional!
UofU Patient
February 04, 2013
We were late going into the exam room, but it was our fault as we were waiting for other family members to get to the clinic. Still, Dr. Akerley and Terry spent plenty of time with us and answered our questions and concerns, and did not rush.
UofU Patient
November 20, 2012
Doctor Akerly is one of the most considerate and caring doctors i've meet. He always gave me options about my care and let me make the decision. I felt like he trusted my judgement and new what i was talking about. I would recomend him highly, he is the best.
UofU Patient
October 31, 2012
We could have had more explanations on medications, but it was all overwhelming and new to me.
UofU Patient
October 29, 2012
Huntsman is the BEST in Utah for cancer. And after having to receive treatment myself, I agree that its the very best place to go for cancer treatments
UofU Patient
September 25, 2012
Dr. Akerly is an amazing doctor, very caring and he explains things very well! The whole staff is very friendly and makes us feel like they care.
UofU Patient
September 17, 2012
I have the utmost confidence in Dr.Akereky and his staff. I have always been treate with respect.
UofU Patient
September 10, 2012
Dr. Ackerley and his associates are wonderful. He is kind, thorough and thoughtful. He has always made us feel like he has all the time in the world to answer our questions and doesn't rush us out of the room.
UofU Patient
August 20, 2012
My experience with the Dr Ackerley and his staff could not have been better. I have always felt very confident in the care and treatment I have received
UofU Patient
June 20, 2012
You can't get better than perfect.
UofU Patient
June 11, 2012
Everything is well explained which helps me and my family understand the treatment.
UofU Patient
June 05, 2012
I trust Dr. Ackerly and his staff. I fell like I am in the best hands.
UofU Patient
April 12, 2012
We came to Huntsman because of your reputation....you are all the best.
UofU Patient
April 06, 2012
Dr. Akerley, and his staff, are wonderful about providing information, and even chatting with us about things other than cancer. They are truly part of our family. Although I do not necessarily wish to be a cancer patient, I have thoroughly enjoyed getting to know each and every one of these people. There are so many, but I will name just a few: Dr. Akerly, Terry VanDuren, Jon Nelson, Kelsey, the two young ladies at the front desk, Amanda, Brigitte, ALL of the medical assistants, ALL of the infusion nurses and their assistants, and anyone I know I have missed. My only problem was with the outpatient pharmacy.
UofU Patient
April 06, 2012
We are very pleased with the care and concern given by the doctor and the entire staff. We are very pleased and trust our confidence and trust with Dr. Ackerly could not be better.
UofU Patient
March 23, 2012
Dr. Akerley always gives the time I feel I need. I don't feel like he is trying to rush through our visit. We are receiving the very best care we could possibly get for my situation.
UofU Patient
March 21, 2012
I couldn't think of any way my care and concerns have been addressed any better.
UofU Patient
February 21, 2012
The staff taking the time to fully explain each detail/issue and never acting as if the patient nor his family member is asking a stupid question is a wonderful aspect of the treatment experience.
UofU Patient
February 17, 2012
I am very pleased with Dr. Akerley and his care. He has always taken the time to talk with me and answer any concerns I have. I am very comfortable with Dr. Akerley and would recommend anyone to him.
UofU Patient
February 15, 2012
I was very pleased that Dr. Akerley spent the right amount of time with me even though he was already behind schedule. I appreciate the fact that he needed to take care of another patient. I appreciate it even more when that patient is me. Since I had already waited so long, I am glad he didn't just rush through my appointment so he could get back on schedule. Thanks!!
UofU Patient
February 10, 2012
Dr. Ackerley is superb .
UofU Patient
February 03, 2012
I have been treated with great respect for 3 years of cancer. I do reccommend it all the time. No place is perfect, not are we patients....... But you are darn close.
UofU Patient
February 01, 2012
Excellent
UofU Patient
January 27, 2012
Am very impressed with Dr .Ackerley and feel he takes a sincere interest in my care.
UofU Patient
January 25, 2012
Dr. Akerley and Julie Smit are wonderful! I've been their patient for several years.
Wallace Akerley, MD
Professor, Department of Medicine, Division of Medical Oncology
Huntsman Cancer Institute
Wallace Akerley, MD, is a professor in the Department of Medicine, Division of Medical Oncology at the University of Utah School of Medicine, co-director of the Thoracic Cancer Program at Huntsman Cancer Institute (HCI), and member of the Experimental Therapeutics Program.
Improvements in cancer treatment evolve from laboratory discoveries, animal studies, and controlled clinical trials. This process is most effective when basic scientists and clinicians work side by side. Huntsman Cancer Institute offers a unique opportunity for basic scientists and clinicians to collaborate in solving problems related to cancer patients. Clinical trials offer promising new treatments to qualifying patients and are a critical step in developing improved cancer treatments.
In addition to his leadership responsibilities, Akerley treats patients with many types of cancer, focusing on lung cancer and melanoma. He participates on the lung cancer committees of two national organizations for cancer treatment: Southwest Oncology Group (SWOG) and National Comprehensive Cancer Network (NCCN). Akerley joined Huntsman Cancer Institute in 2002. Previously, he was director of medical oncology and associate director of the Boston University Cancer Center. He received his medical degree at Brown University in Rhode Island, completed his residency at the University of Southern California (USC), and served additional fellowships at USC/Norris Comprehensive Cancer Center and the Norris Cotton Cancer Center at Dartmouth College in New Hampshire.
Wallace Akerley, MD is a medical oncologist with greater than 30 years experience as a principal investigator on numerous clinical research trials who actively cares for patients with lung cancer and melanoma. With the need for improved cancer treatment, it is imperative to incorporate new treatments when possible. Many of the FDA approved agents were studies at HCI years before they were approved for every day use.
Academic Locations
Huntsman Cancer Institute
801-587-3778
Research Statement
Clinical research, treating patients with the investigational therapies, is the final and most important step of cancer research. Identifying new and improved and/or better tolerated therapy is the primary wish of every cancer physician. There has been a gratifying number of new cancer therapies that were evaluated at HCI and FDA approved in the recent past.
Board Certification and Academic Information
| Academic Departments | Internal Medicine
-
Professor |
| Academic Divisions | Oncology |
| Board Certification | American Board of Internal Medicine (Sub: Hematology) American Board of Internal Medicine (Sub: Medical Oncology) American Board of Internal Medicine (Internal Medicine) National Board of Medical Examiners |
| Cancer Center Programs | Experimental Therapeutics |
Research Interests
- Lung Cancer
- Non-Smoking Lung Cancer
- Radon
- Clinical Trials
Education History
| Fellowship | Dartmouth Hitchcock Medical Ctr. Hematology/Oncology Fellow |
| Fellowship | University of Southern California Oncology Fellow |
| Residency | University of Southern California Internal Medicine Resident |
| Internship | University of Southern California Internal Medicine Intern |
| Professional Medical | Brown University Medicine M.D. |
| Undergraduate | Boston University Engineering B.S. |
Selected Publications - Journal Articles
Journal Article
- Goldberg ME, Montesion M, Young L, Suh J, Greenbowe J, Kennedy M, Giaccone G, Akerley WL, Dowlati A, Creelan BC, Hicks JK, Hesketh PJ, Kelly KL, Riess JW, Miller VA, Stephens PJ, Frampton GM, Ali S, Gregg JP, Albacker LA (2018). Multiple configurations of EGFR exon 20 resistance mutations after first- and third-generation EGFR TKI treatment affect treatment options in NSCLC. PLoS ONE, 13(11), e0208097.
- Akerley WL, Arnaud AM, Reddy B, Page RD (2017 Jun). Impact of a multivariate serum-based proteomic test on physician treatment recommendations for advanced non-small-cell lung cancer. Curr Med Res Opin, 33(6), 1091-1097.
- Stinchcombe TE, Zhang Y, Vokes EE, Schiller JH, Bradley JD, Kelly K, Curran WJ Jr, Schild SE, Movsas B, Clamon G, Govindan R, Blumenschein GR, Socinski MA, Ready NE, Akerley WL, Cohen HJ, Pang HH, Wang X (2017 May 11). Pooled Analysis of Individual Patient Data on Concurrent Chemoradiotherapy for Stage III Non-Small-Cell Lung Cancer in Elderly Patients Compared With Younger Patients Who Participated in US National Cancer Institute Cooperative Group Studies. J Clin Oncol, JCO2016714758.
- Chalmers A, Akerley W (2017 May 08). Retrospective, Multi-Institutional Analysis of Sequential Treatment of Brain Metastases in Treatment-Naive, Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer Should Not Define the Standard of Practice. J Clin Oncol, JCO2017727255.
- Akerley W (2017 May). Biomarker-Based Treatment Selection in Non-Small Cell Lung Cancer. J Natl Compr Canc Netw, 15(5S), 689-691.
- Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman J, Chirieac LR, DAmico TA, DeCamp MM, Dilling TJ, Dobelbower M, Doebele RC, Govindan R, Gubens MA, Hennon M, Horn L, Komaki R, Lackner RP, Lanuti M, Leal TA, Leisch LJ, Lilenbaum R, Lin J, Loo BW Jr, Martins R, Otterson GA, Reckamp K, Riely GJ, Schild SE, Shapiro TA, Stevenson J, Swanson SJ, Tauer K, Yang SC, Gregory K, Hughes M (2017 Apr). Non-Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw, 15(4), 504-535.
- Reck M, Luft A, Szczesna A, Havel L, Kim SW, Akerley W, Pietanza MC, Wu YL, Zielinski C, Thomas M, Felip E, Gold K, Horn L, Aerts J, Nakagawa K, Lorigan P, Pieters A, Kong Sanchez T, Fairchild J, Spigel D (2016 Jul 25). Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer.LID - JCO676601 [pii]. (Epub ahead of print) J Clin Oncol.
- Ettinger DS, Wood DE, Akerley W, Bazhenova LA, Borghaei H, Camidge DR, Cheney RT, Chirieac LR, DAmico TA, Dilling T, Dobelbower M, Govindan R, Hennon M, Horn L, Jahan TM, Komaki R, Lackner RP, Lanuti M, Lilenbaum R, Lin J, Loo BW Jr, Martins R, Otterson GA, Patel JD, Pisters KM, Reckamp K, Riely GJ, Schild SE, Shapiro TA, Sharma N, Swanson SJ, Stevenson J, Tauer K, Yang SC, Gregory K, Hughes M (2016 Jul). NCCN Guidelines Insights: Malignant Pleural Mesothelioma, Version 3.2016. J Natl Compr Canc Netw, 14(7), 825-36.
- Samadder NJ, Smith KR, Hanson H, Pimentel R, Wong J, Boucher K, Akerley W, Gilcrease G, Ulrich CM, Burt RW, Curtin K (2016 Mar). Familial Risk in Patients With Carcinoma of Unknown Primary. JAMA Oncol, 2(3), 340-6.
- Ettinger DS, Wood DE, Akerley W, Bazhenova LA, Borghaei H, Camidge DR, Cheney RT, Chirieac LR, DAmico TA, Dilling TJ, Dobelbower MC, Govindan R, Hennon M, Horn L, Jahan TM, Komaki R, Lackner RP, Lanuti M, Lilenbaum R, Lin J, Loo BW Jr, Martins R, Otterson GA, Patel JD, Pisters KM, Reckamp K, Riely GJ, Schild SE, Shapiro TA, Sharma N, Stevenson J, Swanson SJ, Tauer K, Yang SC, Gregory K, Hughes M (2016 Mar). NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 4.2016. J Natl Compr Canc Netw, 14(3), 255-64.
- Lara PN Jr, Moon J, Hesketh PJ, Redman MW, Williamson SK, Akerley WL 3rd, Hirsch FR, Mack PC, Gandara DR (2016 Mar). SWOG S0709: Randomized Phase II Trial of Erlotinib versus Erlotinib Plus Carboplatin/Paclitaxel in Patients with Advanced Non-Small Cell Lung Cancer and Impaired Performance Status as Selected by a Serum Proteomics Assay. J Thorac Oncol, 11(3), 420-5.
- Carr SR, Akerley W, Hashibe M, Cannon-Albright LA (2015 Nov). Evidence for a genetical contribution to non-smoking-related lung cancer. Thorax, 70(11), 1033-9.
- Kurzrock R, Colevas AD, Olszanski A, Akerley W, Arteaga CL, Carson WE 3rd, Clark JW, DiPersio JF, Ettinger DS, Morgan RJ Jr, Schwartzberg LS, Venook AP, Gocke CD, Tait J, Stewart FM (2015 Nov). NCCN Oncology Research Program's Investigator Steering Committee and NCCN Best Practices Committee Molecular Profiling Surveys. J Natl Compr Canc Netw, 13(11), 1337-46.
- Scagliotti G, von Pawel J, Novello S, Ramlau R, Favaretto A, Barlesi F, Akerley W, Orlov S, Santoro A, Spigel D, Hirsh V, Shepherd FA, Sequist LV, Sandler A, Ross JS, Wang Q, von Roemeling R, Shuster D, Schwartz B (2015 Aug 20). Phase III Multinational, Randomized, Double-Blind, Placebo-Controlled Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Erlotinib Alone in Previously Treated Patients With Locally Advanced or Metastatic Nonsquamous Non-Small-Cell Lung Cancer. J Clin Oncol, 33(24), 2667-74.
- Herde RF, Kokeny KE, Reddy CB, Akerley WL, Hu N, Boltax JP, Hitchcock YJ (2015 Aug 11). Primary Pulmonary Carcinoid Tumor: A Long-term Single Institution Experience. (Epub ahead of print) Am J Clin Oncol.
- Ettinger DS, Wood DE, Akerley W, Bazhenova LA, Borghaei H, Camidge DR, Cheney RT, Chirieac LR, DAmico TA, Demmy TL, Dilling TJ, Dobelbower MC, Govindan R, Grannis FW Jr, Horn L, Jahan TM, Komaki R, Krug LM, Lackner RP, Lanuti M, Lilenbaum R, Lin J, Loo BW Jr, Martins R, Otterson GA, Patel JD, Pisters KM, Reckamp K, Riely GJ, Rohren E, Schild SE, Shapiro TA, Swanson SJ, Tauer K, Yang SC, Gregory K, Hughes M (2015 May). Non-Small Cell Lung Cancer, Version 6.2015. J Natl Compr Canc Netw, 13(5), 515-24.
- Oliver TG, Patel J, Akerley W (2015 Apr). Squamous non-small cell lung cancer as a distinct clinical entity. Am J Clin Oncol, 38(2), 220-6.
- Ettinger DS, Wood DE, Akerley W, Bazhenova LA, Borghaei H, Camidge DR, Cheney RT, Chirieac LR, DAmico TA, Demmy TL, Dilling TJ, Govindan R, Grannis FW Jr, Horn L, Jahan TM, Komaki R, Kris MG, Krug LM, Lackner RP, Lanuti M, Lilenbaum R, Lin J, Loo BW Jr, Martins R, Otterson GA, Patel JD, Pisters KM, Reckamp K, Riely GJ, Rohren E, Schild S, Shapiro TA, Swanson SJ, Tauer K, Yang SC, Gregory K, Hughes M (2014 Dec). Non-small cell lung cancer, version 1.2015. J Natl Compr Canc Netw, 12(12), 1738-61.
- Berek JS, Edwards RP, Parker LP, DeMars LR, Herzog TJ, Lentz SS, Morris RT, Akerley WL, Holloway RW, Method MW, Plaxe SC, Walker JL, Friccius-Quecke H, Krasner CN (2014 Nov). Catumaxomab for the treatment of malignant ascites in patients with chemotherapy-refractory ovarian cancer: a phase II study. Int J Gynecol Cancer, 24(9), 1583-9.
- Nelson RE, Stenehjem D, Akerley W (2013 Dec). A comparison of individualized treatment guided by VeriStrat with standard of care treatment strategies in patients receiving second-line treatment for advanced non-small cell lung cancer: A cost-utility analysis. Lung Cancer, 82(3), 461-8.
- Ettinger DS, Akerley W, Borghaei H, Chang AC, Cheney RT, Chirieac LR, DAmico TA, Demmy TL, Govindan R, Grannis FW Jr, Grant SC, Horn L, Jahan TM, Komaki R, Kong FM, Kris MG, Krug LM, Lackner RP, Lennes IT, Loo BW Jr, Martins R, Otterson GA, Patel JD, Pinder-Schenck MC, Pisters KM, Reckamp K, Riely GJ, Rohren E, Shapiro TA, Swanson SJ, Tauer K, Wood DE, Yang SC, Gregory K, Hughes M (2013 Jun 01). Non-small cell lung cancer, version 2.2013. J Natl Compr Canc Netw, 11(6), 645-53; quiz 653.
- Ettinger DS, Riely GJ, Akerley W, Borghaei H, Chang AC, Cheney RT, Chirieac LR, DAmico TA, Demmy TL, Govindan R, Grannis FW Jr, Grant SC, Horn L, Jahan TM, Komaki R, Kong FM, Kris MG, Krug LM, Lackner RP, Lennes IT, Loo BW Jr, Martins R, Otterson GA, Patel JD, Pinder-Schenck MC, Pisters KM, Reckamp K, Rohren E, Shapiro TA, Swanson SJ, Tauer K, Wood DE, Yang SC, Gregory K, Hughes M (2013 May 01). Thymomas and thymic carcinomas: Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw, 11(5), 562-76.
- Akerley WL, Nelson RE, Cowie RH, Spinella DG, Hornberger J (2013 May). The impact of a serum based proteomic mass spectrometry test on treatment recommendations in advanced non-small-cell lung cancer. Curr Med Res Opin, 29(5), 517-25.
- Akerley W, Boucher K, Rich N, Egbert L, Harker G, Bylund J, Van Duren T, Reddy C (2013 Mar). A phase II study of bevacizumab and erlotinib as initial treatment for metastatic non-squamous, non-small cell lung cancer with serum proteomic evaluation. Lung Cancer, 79(3), 307-11.
- Kalemkerian GP, Akerley W, Bogner P, Borghaei H, Chow LQ, Downey RJ, Gandhi L, Ganti AK, Govindan R, Grecula JC, Hayman J, Heist RS, Horn L, Jahan T, Koczywas M, Loo BW Jr, Merritt RE, Moran CA, Niell HB, OMalley J, Patel JD, Ready N, Rudin CM, Williams CC Jr, Gregory K, Hughes M (2013 Jan 01). Small cell lung cancer. J Natl Compr Canc Netw, 11(1), 78-98.
- Grossmann KF, Colman H, Akerley WA, Glantz M, Matsuoko Y, Beelen AP, Yu M, De Groot JF, Aiken RD, Olson JJ, Evans BA, Jensen RL (2012 Nov). Phase I trial of verubulin (MPC-6827) plus carboplatin in patients with relapsed glioblastoma multiforme. J Neurooncol, 110(2), 257-64.
- Ettinger DS, Akerley W, Borghaei H, Chang AC, Cheney RT, Chirieac LR, DAmico TA, Demmy TL, Ganti AK, Govindan R, Grannis FW Jr, Horn L, Jahan TM, Jahanzeb M, Kessinger A, Komaki R, Kong FM, Kris MG, Krug LM, Lennes IT, Loo BW Jr, Martins R, OMalley J, Osarogiagbon RU, Otterson GA, Patel JD, Pinder-Schenck MC, Pisters KM, Reckamp K, Riely GJ, Rohren E, Swanson SJ, Wood DE, Yang SC, Hughes M, Gregory KM (2012 Oct 01). Non-small cell lung cancer. J Natl Compr Canc Netw, 10(10), 1236-71.
- Margolin KA, Moon J, Flaherty LE, Lao CD, Akerley WL 3rd, Othus M, Sosman JA, Kirkwood JM, Sondak VK (2012 Feb 15). Randomized phase II trial of sorafenib with temsirolimus or tipifarnib in untreated metastatic melanoma (S0438). Clin Cancer Res, 18(4), 1129-37.
- Ettinger DS, Akerley W, Borghaei H, Chang A, Cheney RT, Chirieac LR, DAmico TA, Demmy TL, Ganti AK, Govindan R, Grannis FW, Horn L, Jahan TM, Jahanzeb M, Kessinger A, Komaki R, Kong FM, Kris MG, Krug LM, Lennes IT, Loo BW, Martins R, OMalley J, Osarogiagbon RU, Otterson GA, Patel JD, Schenck MP, Pisters KM, Reckamp K, Riely GJ, Rohren E, Swanson SJ, Wood DE, Yang SC (2012 Jan). Malignant pleural mesothelioma. J Natl Compr Canc Netw, 10(1), 26-41.
- Poruk KE, Firpo MA, Boucher KM, Akerley WL, Neumayer LA, Sklow B, Scaife CL, Mulvihill SL (). Assessment of Serum Platelet Factor 4 as a Predictive Marker for VTE and as a Prognostic Biomarker in Pancreatic, Colorectal, Breast, and Lung Cancer. J Surg Res, 172(2), 242-243.
- Kalemkerian GP, Akerley W, Bogner P, Borghaei H, Chow L, Downey RJ, Gandhi L, Ganti AK, Govindan R, Grecula JC, Hayman J, Heist RS, Horn L, Jahan TM, Koczywas M, Moran CA, Niell HB, OMalley J, Patel JD, Ready N, Rudin CM, Williams CC Jr (2011 Oct). Small cell lung cancer. J Natl Compr Canc Netw, 9(10), 1086-113.
- Sequist LV, von Pawel J, Garmey EG, Akerley WL, Brugger W, Ferrari D, Chen Y, Costa DB, Gerber DE, Orlov S, Ramlau R, Arthur S, Gorbachevsky I, Schwartz B, Schiller JH (2011 Aug 20). Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer. J Clin Oncol, 29(24), 3307-15.
- Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, Jouary T, Schadendorf D, Ribas A, ODay SJ, Sosman JA, Kirkwood JM, Eggermont AM, Dreno B, Nolop K, Li J, Nelson B, Hou J, Lee RJ, Flaherty KT, McArthur GA, BRIM-3 Study Group, Akerley WL (). Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med, 2011 Jun(364(26):), 2507-16.
- Akerley W, Edwards S, Wilson R, Van Duren T, Akerley D, Tranter S, Sharry S (). Awareness of Radon - Associated Health Risks in Utah. Utah's Health: An Annual Review, 16(2011), 58-60.
- Tsimberidou AM, Akerley W, Schabel MC, Hong DS, Uehara C, Chhabra A, Warren T, Mather GG, Evans BA, Woodland DP, Swabb EA, Kurzrock R (2010 Dec). Phase I clinical trial of MPC-6827 (Azixa), a microtubule destabilizing agent, in patients with advanced cancer. Mol Cancer Ther, 9(12), 3410-9.
- Ettinger DS, Akerley W, Bepler G, Blum MG, Chang A, Cheney RT, Chirieac LR, DAmico TA, Demmy TL, Govindan R, Grannis FW Jr, Jahan T, Johnson DH, Kessinger A, Komaki R, Kong FM, Kris MG, Krug LM, Le QT, Lennes IT, Martins R, OMalley J, Osarogiagbon RU, Otterson GA, Patel JD, Pisters KM, Reckamp K, Riely GJ, Rohren E, Swanson SJ, Wood DE, Yang SC (2010 Nov). Thymic malignancies. J Natl Compr Canc Netw, 8(11), 1302-15.
- Hodi FS, ODay SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbe C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ (2010 Aug 19). Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med, 363(8), 711-23.
- Ettinger DS, Akerley W, Bepler G, Blum MG, Chang A, Cheney RT, Chirieac LR, DAmico TA, Demmy TL, Ganti AK, Govindan R, Grannis FW Jr, Jahan T, Jahanzeb M, Johnson DH, Kessinger A, Komaki R, Kong FM, Kris MG, Krug LM, Le QT, Lennes IT, Martins R, OMalley J, Osarogiagbon RU, Otterson GA, Patel JD, Pisters KM, Reckamp K, Riely GJ, Rohren E, Simon GR, Swanson SJ, Wood DE, Yang SC (2010 Jul). Non-small cell lung cancer. J Natl Compr Canc Netw, 8(7), 740-801.
- Socinski MA, Langer CJ, Huang JE, Kolb MM, Compton P, Wang L, Akerley W (2009 Nov 01). Safety of bevacizumab in patients with non-small-cell lung cancer and brain metastases. J Clin Oncol, 27(31), 5255-61.
- Stinchcombe TE, Hodgson L, Herndon JE 2nd, Kelley MJ, Cicchetti MG, Ramnath N, Niell HB, Atkins JN, Akerley W, Green MR, Vokes EE (2009 Sep). Treatment outcomes of different prognostic groups of patients on cancer and leukemia group B trial 39801: induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for unresectable stage III non-small cell lung cancer. J Thorac Oncol, 4(9), 1117-25.
- Akerley W, Boucher KM, Bentz JS, Arbogast K, Walters T (2009 Feb). A phase II study of erlotinib as initial treatment for patients with stage IIIB-IV non-small cell lung cancer. J Thorac Oncol, 4(2), 214-9.
- Kalemkerian GP, Akerley W, Downey RJ, Ettinger DS, fossella F, Grecula JC et al (03/06/2008).
Small cell lung cancer
. J Natl Compr Canc Netw, 6(3), 294-314. - Ettinger DS, Akerley W, Bepler G, Chang A, cheney Rt, Chirieac LR, DAmico TA, Demmy TL et al (03/06/2008).
Non-small cell lung cancer
. J Natl Compr Canc Netw, 6(3), 228-269. - Kalemkerian GP, Akerley W, Downey RJ, Ettinger DS, Fossella F, Grecula JC, Jahan T, Johnson BE, Kessinger A, Koczywas M, Langer CJ, Martins R, Niell HB, Pan CC, Ramnath N, Ready N, Robert F, Williams CC Jr (2008 Mar). Small cell lung cancer. J Natl Compr Canc Netw, 6(3), 294-314.
- Ettinger DS, Akerley W, Bepler G, Chang A, Cheney RT, Chirieac LR, DAmico TA, Demmy TL, Feigenberg SJ, Figlin RA, Govindan R, Grannis FW Jr, Jahan T, Jahanzeb M, Kessinger A, Komaki R, Kris MG, Langer CJ, Le QT, Martins R, Otterson GA, Patel JD, Robert F, Sugarbaker DJ, Wood DE (2008 Mar). Non-small cell lung cancer. J Natl Compr Canc Netw, 6(3), 228-69.
- Akerley W, McCoy J, Hesketh PJ, Goodwin JW, Bearden JD, Atkins JN, Chansky K, Crowley JJ, Gandara DR (2007 Jun). Gemcitabine and irinotecan for patients with untreated extensive stage small cell lung cancer: SWOG 0119. J Thorac Oncol, 2(6), 526-30.
- Vokes EE, Herndon JE 2nd, Kelley MJ, Cicchetti MG, Ramnath N, Neill H, Atkins JN, Watson DM, Akerley W, Green MR (2007 May 01). Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III Non-small-cell lung cancer: Cancer and Leukemia Group B. J Clin Oncol, 25(13), 1698-704.
- Fanucchi MP, Fossella FV, Belt R, Natale R, Fidias P, Carbone DP, Govindan R, Raez LE, Robert F, Ribeiro M, Akerley W, Kelly K, Limentani SA, Crawford J, Reimers HJ, Axelrod R, Kashala O, Sheng S, Schiller JH (2006 Nov 01). Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancer. J Clin Oncol, 24(31), 5025-33.
- Akerley W, Safran H, Zaner K, Ready N, Mega T, Kennedy T (2006 Sep 01). Phase II trial of weekly paclitaxel and gemcitabine for previously untreated, stage IIIB-IV nonsmall cell lung cancer. Cancer, 107(5), 1050-4.
- Kim DW, Shyr Y, Chen H, Akerley W, Johnson DH, Choy H (2005 Nov 15). Response to combined modality therapy correlates with survival in locally advanced non-small-cell lung cancer. Int J Radiat Oncol Biol Phys, 63(4), 1029-36.
- Kim DW, Shyr Y, Shaktour B, Akerley W, Johnson DH, Choy H (2005 Nov). Long term follow up and analysis of long term survivors in patients treated with paclitaxel-based concurrent chemo/radiation therapy for locally advanced non-small cell lung cancer. Lung Cancer, 50(2), 235-45.
- Akerley W, Herndon JE Jr, Lyss AP, Choy H, Turrisi A, Graziano S, Williams T, Zhang C, Vokes EE, Green MR (2005 Jul). Induction paclitaxel/carboplatin followed by concurrent chemoradiation therapy for unresectable stage III non-small-cell lung cancer: a limited-access study--CALGB 9534. Clin Lung Cancer, 7(1), 47-53.
- Socinski MA, Zhang C, Herndon JE 2nd, Dillman RO, Clamon G, Vokes E, Akerley W, Crawford J, Perry MC, Seagren SL, Green MR (2004 Jul). Combined modality trials of the Cancer and Leukemia Group B in stage III non-small-cell lung cancer: analysis of factors influencing survival and toxicity. Ann Oncol, 15(7), 1033-41.
- Akerley W, Herndon JE, Egorin MJ, Lyss AP, Kindler HL, Savarese DM, Sherman CA, Rosen DM, Hollis D, Ratain MJ, Green MR (2003 May 15). Weekly, high-dose paclitaxel in advanced lung carcinoma: a phase II study with pharmacokinetics by the Cancer and Leukemia Group B. Cancer, 97(10), 2480-6.
- Akerley W, Herndon J, Green M, et al (2003). Dose-Dense Weekly Paclitaxel and Pharmacologic Evaluation for Patients with Stage IIIB-IV Non-Small Cell Lung Cancer: A Phase II Trial of Cancer and Leukemia Group B (CALGB 9731/9765). Cancer, 97, 2480-6.
- Akerley W, Butera J, Wehbe T, Noto R, Stein B, Safran H, Cummings F, Sambandam S, Maynard J, Di Rienzo G, Leone L (2002 Mar 15). A multiinstitutional, concurrent chemoradiation trial of strontium-89, estramustine, and vinblastine for hormone refractory prostate carcinoma involving bone. Cancer, 94(6), 1654-60.
- Blackstock AW, Herndon JE 2nd, Paskett ED, Perry MC, Graziano SL, Muscato JJ, Kosty MP, Akerley WL, Holland J, Fleishman S, Green MR (2002 Feb 20). Outcomes among African-American/non-African-American patients with advanced non-small-cell lung carcinoma: report from the Cancer and Leukemia Group B. J Natl Cancer Inst, 94(4), 284-90.
- Akerley W, Butera J, Wehbe T, Noto R, Stein B, Safran H, Cummings F, Sambandam S, Maynard J, Di Rienzo G, Leone L (2002). A Multiinstitutional, Concurrent Chemoradiation Trial of Strontium-89, Estramustine, and Vinblastine for Hormone Refractory Prostate Carcinoma Involving Bone. Cancer, 94(6), 1654-1660.
- Makarovskiy A, Siryaporn E, Hixon D, Akerley W (2002). Survival of Docetaxel-resistant Prostate Cancer Cells Depends on Phenotype Alterations and Continuity of Drug Exposure. Cell Mol Life Sci, 59, 1198-1211.
- Blackstock A, Herndon J, Paskett E, Perry M, Graziano S, Muscato, Kosty M, Akerley W, Holland J, Fleishman S, Green M (2002). Outcomes Among African-American and Non African-American Patients with Advanced Non-Small Cell Lung Cancer: A Report from the CALGB. J Natl Cancer Inst, 94(4), 284-90.
- Akerley W, Rathore R, Ready N, Leone L, Sikov W, Safran H, Kennedy T (2002). A phase I study of a weekly schedule of paclitaxel and carboplatin in patients with advanced carcinoma. Cancer, 95(9), 2000-5.
- Akerley W (2001 Mar). Recent developments in weekly paclitaxel therapy in lung cancer. Curr Oncol Rep, 3(2), 165-9.
- Gurevich I, Akerley W (2001). Treatment of the Jaundiced Patient with Breast Carcinoma. Cancer, 91(4), 660-663.
- Akerley W (2001). Recent Development in Weekly Paclitaxel Therapy of Lung Cancer. Curr Oncol Rep, 3(2), 165-169.
- Wanebo H, Chougule P, Ready N, Safran H, Akerley W, Koness R, McRae R, Nigri P, Leone L, Kennedy T, Webber B (2001). Surgical Resection is Necessary to Maximize Tumor Control In Function Preserving, Aggressive Chemoradiation Protocols for Advanced Squamous Cancer of the Head and Neck (Stage III and IV). Ann Surg Oncol, 8, 644-50.
- Savarese DM, Halabi S, Hars V, Akerley WL, Taplin ME, Godley PA, Hussain A, Small EJ, Vogelzang NJ (2001). Phase II Study of Docetaxel, Estramustine, and Low-dose Hydrocortisone in Men with Hormone-refractory Prostate Cancer: a final report of CALGB 9780. J Clin Oncol, 19(9), 2509-16.
- Jaeckle KA, Phuphanich S, Bent MJ, Aiken R, Batchelor T, Campbell T, Fulton D, Gilbert M, Heros D, Rogers L, ODay SJ, Akerley W, Allen J, Baidas S, Gertler SZ, Greenberg HS, LaFollette S, Lesser G, Mason W, Recht L, Wong E, Chamberlain MC, Cohn A, Glantz MJ, Gutheil JC, Maria B, Moots P, New P, Russell C, Shapiro W, Swinnen L, Howell SB (2001 Jan). Intrathecal treatment of neoplastic meningitis due to breast cancer with a slow-release formulation of cytarabine. Br J Cancer, 84(2), 157-63.
- King TC, Akerley W, Fan AC, Moore T, Mangray S, Hsiu Chen M, Safran H (2000 Aug 15). p53 mutations do not predict response to paclitaxel in metastatic nonsmall cell lung carcinoma. Cancer, 89(4), 769-73.
- Akerley W 3rd (2000 Apr). Paclitaxel in advanced non-small cell lung cancer : an alternative high-dose weekly schedule. Chest, 117(4 Suppl 1), 152S-155S.
- Dupuy D, Zagoria R, Akerley W, Mayo-Smith W, Kavanagh P, Safran H (2000). Percutaneous Radiofrequency Ablation of Malignancies in the Lung. Am J Roentgenol Radium Ther Nucl Med, 174(1), 57-9.
- Dupuy DE, Zagoria RJ, Akerley W, Mayo-Smith WW, Kavanagh PV, Safran H (2000 Jan). Percutaneous radiofrequency ablation of malignancies in the lung. AJR Am J Roentgenol, 174(1), 57-9.
- Akerley W (2000). Secondary Leukemia: Twice is a Coincidence? Cancer, 88(3), 497-9.
- Akerley W (2000). Paclitaxel in Advanced Non-small Cell Lung Cancer: An Alternative High-dose Weekly Schedule. Chest, 117:4 (suppl 1), 152-5.
- King T, Akerley W, Fan A, Walsh K, Mangray S, Chen M, Safran H (2000). P53 Mutations Do Not Predict Response to Paclitaxel for Metastatic Non-Small Cell Lung Cancer. Cancer, 89(4), 769-73.
- Wanebo HJ, Chougule P, Ready N, Koness RJ, Akerley W, McRae R, Nigri P, Leone L, Webber B, Safran H (1999 Apr). Preoperative paclitaxel, carboplatin, and radiation therapy in advanced head and neck cancer (stage III and IV). Semin Radiat Oncol, 9(2 Suppl 1), 77-84.
- Akerley W, Choy H (1999 Apr). Single-agent paclitaxel and radiation for non-small cell lung cancer. Semin Radiat Oncol, 9(2 Suppl 1), 85-9.
- Chougule PB, Akhtar MS, Akerley W, Ready N, Safran H, McRae R, Nigri P, Bellino J, Koness J, Radie-Keane K, Wanebo H (1999 Apr). Chemoradiotherapy for advanced inoperable head and neck cancer: A phase II study. Semin Radiat Oncol, 9(2 Suppl 1), 58-63.
- Akerley W and Choy H (1999). Single Agent Paclitaxel and Radiation for Non-Small Cell Lung Cancer. Semin Radiat Oncol, 9(2) suppl 1, 85-89.
- Glantz M, Kim L, Choy H, Akerley W (1999). Concurrent Chemotherapy and Radiotherapy in Patients with Brain Tumors. Oncology, 13(10) suppl 5, 78-82.
- Wanebo H, Chougule P, Ready N, Koness R, Akerley W, McRae R, Nigri P, Leone L, Webber B, Safran H (1999). Preoperative Paclitaxel, Carboplatin and Radiation Therapy in Advanced Head and Neck Cancer. Semin Radiat Oncol, 9(2) suppl 1, 77-84.
- Chougule P, Akhtar M, Akerley W, Ready N, Safran H, McRae R, Nigri P, Bellino J, Koness R, Radie-Kane K, and Wanebo H (1999). Chemoradiotherapy for Advanced Inoperable Head and Neck Cancer: A Phase II Study. Semin Radiat Oncol, 9(2) suppl 1, 58-63.
- Choy H, Akerley W, Safran H, Graziano S, Chung C, Williams T, Cole B, Kennedy T (1998 Oct). Multiinstitutional phase II trial of paclitaxel, carboplatin, and concurrent radiation therapy for locally advanced non-small-cell lung cancer. J Clin Oncol, 16(10), 3316-22.
- Choy H, Safran H, Akerley W, Graziano SL, Bogart JA, Cole BF (1998 Aug). Phase II trial of weekly paclitaxel and concurrent radiation therapy for locally advanced non-small cell lung cancer. Clin Cancer Res, 4(8), 1931-6.
- Glantz MJ, Cole BF, Recht L, Akerley W, Mills P, Saris S, Hochberg F, Calabresi P, Egorin MJ (1998 Apr). High-dose intravenous methotrexate for patients with nonleukemic leptomeningeal cancer: is intrathecal chemotherapy necessary? J Clin Oncol, 16(4), 1561-7.
- Recht LD, Glantz MJ, Meitner P, Glantz L, Akerley W, Wahlberg L, Saris S, Cole BF (1998 Feb). Unexpected in vitro chemosensitivity of malignant gliomas to 4-hydroxyperoxycyclophosphamide (4-HC). J Neurooncol, 36(3), 201-8.
- Akerley W (1998). Oncology: Combined Modalilty Therapy in Non-Small Cell Lung Cancer. Disease Management Digest, 2(3), 14-15.
- Akerley W, Glantz M, Choy H, Rege V, Sambandam S, Joseph P, Yee L, Rodrigues B, Wingate P, Leone L (1998 Jan). Phase I trial of weekly paclitaxel in advanced lung cancer. J Clin Oncol, 16(1), 153-8.
- Clamon G, Herndon J, Akerley W, Green M (1998 Jan). Subcutaneous interleukin-2 as initial therapy for patients with extensive small cell lung cancer: a phase II trial of Cancer and Leukemia Group B. Lung Cancer, 19(1), 25-9.
- Chougule P, Wanebo H, Akerley W, McRae R, Nigri P, Leone L, Safran H, Ready N, Koness RJ, Radie-Keane K, Cole B (1997 Dec). Concurrent paclitaxel, carboplatin, and radiotherapy in advanced head and neck cancers: a phase II study--preliminary results. Semin Oncol, 24(6 Suppl 19), S19-57-S19-61.
- Wanebo HJ, Chougule P, Akerley WL 3rd, Koness RJ, McRae R, Nigri P, Leone L, Ready N, Safran H, Webber B, Cole B (1997 Nov). Preoperative chemoradiation coupled with aggressive resection as needed ensures near total control in advanced head and neck cancer. Am J Surg, 174(5), 518-22.
- Akerley W, Sikov WM, Cummings F, Safran H, Strenger R, Marchant D (1997 Oct). Weekly high-dose paclitaxel in metastatic and locally advanced breast cancer: a preliminary report. Semin Oncol, 24(5 Suppl 17), S17-87-S17-90.
- Akerley W, Choy H, Safran H, Sikov W, Rege V, Sambandam S, Wittels E (1997 Aug). Weekly paclitaxel in patients with advanced lung cancer: preliminary data from a phase II trial. Semin Oncol, 24(4 Suppl 12), S12-10-S12-13.
- Safran H, King TP, Choy H, Hesketh PJ, Wolf B, Altenhein E, Sikov W, Rosmarin A, Akerley W, Radie-Keane K, Cicchetti G, Lopez F, Bland K, Wanebo HJ (1997 Mar). Paclitaxel and concurrent radiation for locally advanced pancreatic and gastric cancer: a phase I study. J Clin Oncol, 15(3), 901-7.
- Choy H, Akerley W, Devore R (1997). Paclitaxel in Combined Modality Therapy for Locally Advanced Non-Small Cell Lung Cancer. Advances in Oncology, 13(4), 17-24.
- Choy H, King T, Akerley W, Safran H (1997). Paclitaxel and Concurrent Radiation for Lung, Pancreatic and Gastric Carcinomas: Significance of p53 Gene Mutations for Treatment Response. Semin Radiat Oncol, 7(3), s77-81.
- Choy H, Akerley W, Safran H, Clark J, Rege V, Papa A, Glantz M, Puthawala Y, Soderberg C, Leone L (1997). Phase I Trial of Outpatient Weekly Paclitaxel and Concurrent Radiation Therapy for Advanced Non-Small Cell Lung Cancer. Classic Papers and Current Comments, 2(1), 167-71.
- Choy H, Akerley W, Safran H, Graziano S (1997). Concurrent Weekly Paclitaxel and Radiation Therapy for Locally Advanced NSCLC. Lung Cancer, 18(S2), 152.
- Makarovskiy A, Ackerley W, Wojcik W, Halpert G, Stein B, Carreiro M, Hixson D (1997). Application of Immunomagnetic Beads in Combination with RT-PCR for the Detection of Circulating Prostate Cancer Cells. J Clin Lab Anal, 11, 346-50.
- Akerley W (1996 Dec). Phase I/II trial of weekly paclitaxel in patients with advanced lung cancer. Semin Oncol, 23(6 Suppl 16), 55-8.
- Glantz MJ, Choy H, Akerley W, Kearns CM, Egorin MJ, Rhodes CH, Cole BF (1996 Dec). Weekly paclitaxel with and without concurrent radiation therapy: toxicity, pharmacokinetics, and response. Semin Oncol, 23(6 Suppl 16), 128-35.
- Choy H, Akerley W, Safran H, Graziano S, Chung C (1996 Dec). Paclitaxel plus carboplatin and concurrent radiation therapy for patients with locally advanced non-small cell lung cancer. Semin Oncol, 23(6 Suppl 16), 117-9.
- Akerley W 3rd, Glantz M, Choy H (1996 Oct). Preliminary results of a phase I study of weekly paclitaxel infusion in patients with non-small cell lung cancer. Semin Oncol, 23(5 Suppl 12), 14-8.
- Choy H, Akerley W, Glantz M, Safran H, Graziano S, Chung C (1996 Jul). Concurrent Paclitaxel and Radiation Therapy for Solid Tumors. Cancer Control, 3(4), 310-318.
- Glantz MJ, Cole BF, Friedberg MH, Lathi E, Choy H, Furie K, Akerley W, Wahlberg L, Lekos A, Louis S (1996 Apr). A randomized, blinded, placebo-controlled trial of divalproex sodium prophylaxis in adults with newly diagnosed brain tumors. Neurology, 46(4), 985-91.
- Glantz M, Choy H, Akerley W, Kearns C, Egorin M, Rhodes H, Cole B (1996). Weekly Paclitaxel With and Without Concurrent Radiation Therapy: Toxicity, Pharmacokinetics and Response. Semin Oncol, 23(6) Suppl 16, 128-135.
- Akerley W, Glantz M, Choy H (1996). Phase I Study of Weekly Outpatient Paclitaxel in Advanced and Metastatic Non-small Cell Lung Cancer. Semin Oncol, 23(5), Suppl 12, 14-18.
- Clark J, Sikov W, Cummings F, Browne M, Akerley W, Wanebo H, Weitberg A, Kennedy T, Cole B, Bigley J, Beitz J, Darnowski J (1996). Phase II study of 5-fluoruracil leucovorin and azidothymidine in patients with metastatic colorectal cancer. J Cancer Res Clin Oncol, 122(9), 554-8.
- Glantz MJ, Choy H, Kearns CM, Akerley W, Egorin MJ (1995 Oct). Weekly, outpatient paclitaxel and concurrent cranial irradiation in adults with brain tumors: preliminary results and promising directions. Semin Oncol, 22(5 Suppl 12), 26-32.
- Glantz MJ, Hall WA, Cole BF, Chozick BS, Shannon CM, Wahlberg L, Akerley W, Marin L, Choy H (1995 Jun 15). Diagnosis, management, and survival of patients with leptomeningeal cancer based on cerebrospinal fluid-flow status. Cancer, 75(12), 2919-31.
- Akerley W, Choy H (1995 Jun). Concurrent paclitaxel and thoracic radiation for advanced non-small cell lung cancer. Lung Cancer, 12 Suppl 2, S107-15.
- Choy H, Akerley W, Safran H, Clark J, Rege V, Papa A, Glantz M, Puthawala Y, Soderberg C, Leone L (1994 Dec). Phase I trial of outpatient weekly paclitaxel and concurrent radiation therapy for advanced non-small-cell lung cancer. J Clin Oncol, 12(12), 2682-6.
- Miller ME, Dores GM, Thorpe SL, Akerley WL (1994 Jun 15). Paradoxical influence of estrogenic hormones on platelet-endothelial cell interactions. Thromb Res, 74(6), 577-94.
- Akerley WL 3rd, Moritz TE, Ryan LS, Henderson WG, Zacharski LR (1993 Jul 26). Racial comparison of outcomes of male Department of Veterans Affairs patients with lung and colon cancer. Arch Intern Med, 153(14), 1681-8.
- Posner M, Martin A, Slapak CA, Clark JW, Cummings FJ, Robert NJ, Sikov W, Akerley W (1992 Jun). A phase II trial of continuous infusion cisplatin and 5-fluorouracil with oral calcium leucovorin in colorectal carcinoma. Am J Clin Oncol, 15(3), 239-41.
- Akerley WL 3rd, Guyre PM, Davis BH (1991 Feb 01). Neutrophil activation through high-affinity Fc gamma receptor using a monomeric antibody with unique properties. Blood, 77(3), 607-15.
- Grunberg SM, Ehler E, McDermed JE, Akerley WL (1988 Aug 03). Oral metoclopramide with or without diphenhydramine: potential for prevention of late nausea and vomiting induced by cisplatin. J Natl Cancer Inst, 80(11), 864-8.
- Grunberg SM, Akerley WL, Krailo MD, Johnson KB, Baker CR, Cariffe PA (1986). Comparison of metoclopramide and metoclopramide plus dexamethasone for complete protection from cisplatinum-induced emesis. Cancer Invest, 4(5), 379-85.
Review
- Sandler A, Hirsh V, Reck M, von Pawel J, Akerley W, Johnson DH (2012 Oct). An evidence-based review of the incidence of CNS bleeding with anti-VEGF therapy in non-small cell lung cancer patients with brain metastases. [Review]. Lung Cancer, 78(1), 1-7.
- Soffietti R, Akerley W, Jensen RL, Bischoff J, Regierer AC (2009 Aug). The role of intra-cerebrospinal fluid treatment and prophylaxis in patients with solid tumors. [Review]. Semin Oncol, 36(4 Suppl 2), S55-68.
- Figlin RA, Brown E, Armstrong AJ, Akerley W, Benson AB 3rd, Burstein HJ, Ettinger DS, Febbo PG, Fury MG, Hudes GR, Kies MS, Kwak EL, Morgan RJ Jr, Mortimer J, Reckamp K, Venook AP, Worden F, Yen Y (2008 Sep). NCCN Task Force Report: mTOR inhibition in solid tumors. [Review]. J Natl Compr Canc Netw, 6 Suppl 5, S1-20; quiz S21-2.
- Majer M, Akerley W, Kuwada SK (2007 Sep). Oncologists' current opinion on the treatment of colon carcinoma. [Review]. Anticancer Agents Med Chem, 7(5), 492-503.
- Majer M, Akerley W, Kuwada SK (09/01/2007).
Oncologists' current opinion on the treatment of colon carcinoma
. [Review]. Anticancer Agents Med Chem, 7(5), 492-503. - Glantz MJ, Kim L, Choy H, Akerley W (1999 Oct). Concurrent chemotherapy and radiotherapy in patients with brain tumors. [Review]. Oncology (Williston Park), 13(10 Suppl 5), 78-82.
- Choy H, Akerley W, DeVore RF 3rd (1999 Feb). Concurrent paclitaxel, carboplatin, and radiation therapy for locally advanced non-small cell lung cancer. [Review]. Semin Oncol, 26(1 Suppl 2), 36-43.
- Choy H, Akerley W, Devore R (1998 Jan). Paclitaxel, carboplatin and radiation therapy for non-small-cell lung cancer. [Review]. Oncology (Williston Park), 12(1 Suppl 2), 80-6.
- Akerley WL 3rd (1995 Oct). Contemporary adjuvant treatment of breast cancer. [Review]. Surg Oncol Clin N Am, 4(4), 685-99.
- Akerley WL 3rd (1995 Sep). Adjuvant treatment of breast cancer. [Review]. R I Med, 78(9), 250-3.
Book Chapter
- Choy H, Akerley W, Safran H (1998). Taxanes in Lung Cancer. In Johnson CH; Clastersky J (Ed.), Taxanes and Radiation Therapy in Solid Tumors (pp. 181-198). New York: Marcel Dekker.
- Akerley W and Calabresi P (1994). The Rational Use of Advanced Medical Technology with the Elderly. In In F. Homburger (Ed.), Advanced Cancer Treatment for the Elderly (pp. 236-49). Springer Publishing Company.
Case Report
- Anker CJ, Ribas A, Grossmann AH, Chen X, Narra KK, Akerley W, Andtbacka RH, Noyes RD, Shrieve DC, Grossmann KF (2013 Jun 10). Severe liver and skin toxicity after radiation and vemurafenib in metastatic melanoma. J Clin Oncol, 31(17), e283-7.
- Anker CJ, Dechet C, Isaac JC, Akerley W, Shrieve DC (2008 Mar 01). Small-cell carcinoma of the prostate. J Clin Oncol, 26(7), 1168-71.
- Gurevich I, Akerley W (2001 Feb 15). Treatment of the jaundiced patient with breast carcinoma: case report and alternate therapeutic strategies. Cancer, 91(4), 660-3.
- Wehbe T, Glantz M, Choy H, Glantz L, Cortez S, Akerley W 3rd, Mills P, Cole B (1998 Sep). Histologic evidence of a radiosensitizing effect of Taxol in patients with astrocytomas. J Neurooncol, 39(3), 245-51.
- Wehbe TW, Stein BS, Akerley WL (1997 Oct). Prostate-specific antigen response to withdrawal of megestrol acetate in a patient with hormone-refractory prostate cancer. Mayo Clin Proc, 72(10), 932-4.
- Wehbe T, Stein B, Akerley W (1997). Megestrol Acetate Withdrawal Syndrome in Hormone Refractory Prostate Carcinoma. Report # (72(10)). Mayo Clin Proc.
- Kim WY, Wehbe TW, Akerley W 3rd (1996 Nov). A woman with a balanced autosomal translocation who received chemotherapy while pregnant. Med Health R I, 79(11), 396-9.
Editorial
Letter
- Akerley W and Wehbe T (1998). Induction of PSA Expression by Synthetic Progestins in Patients with Prostate and Breast Cancer [Letter to the editor]. Mayo Clin Proc, 706-7.
- Akerley W (1997 Jan). Two doses of paclitaxel and statistical analysis: try, try, try again [Letter to the editor]. J Clin Oncol, 15(1), 408-9.
Abstract
- J S Berek, R P Edwards, L Parker, L R DeMars, T J Herzog, S S Lentz, R Morris, W L Akerley, R W Holloway, M Method, S C Plaxe, J L Walker, T Schindler, E Schulze, C N Krasner, Cooperative Ovarian Cancer Group COGI, Stanford Cancer Center, Stanford, CA, Magee-Womens Hospital of the University of Pittsburgh Medical Center, Pittsburgh, PA, James Graham Brown Cancer Center, University of Louisville, Louisville, KY, Dartmouth-Hitchcock Medical Center, Lebanon, NH, Columbia University Cancer Center, New York, NY, WFU Baptist Medical Center, Winston-Salem, NC, Karmanos Cancer InstituteWayne State University, Detroit, MI, Huntsman Cancer Institute, Salt Lake City, UT, Florida Hospital Cancer Institute, Orlando, FL, Northern Indiana Cancer Research Consortium, South Bend, IN, University of California, San Diego, La Jolla, CA, University of Oklahoma Health Sciences Center, Oklahoma City, OK, Fresenius Biotech GmbH, Munich, Germany, Massachusetts General HospitalDana-Farber Harvard Cancer Center, Boston, MA (). Catumaxomab treatment of malignant ascites in patients with chemotherapy-refractory ovarian cancer: A phase II study [Abstract]. J Clin Oncol, 29(suppl), 5048.
- J P Fruehauf, Z Eroglu, K M Kong, J G Jakowatz, W L Akerley, W E Samlowski, UCI Comprehensive Cancer Center, Orange, CA, University of California, Irvine Medical Center, Orange, CA, Huntsman Cancer Institute, Salt Lake City, UT, Nevada Cancer Institute, Las Vegas, NV (). A single-arm phase II trial evaluating docetaxel, vinorelbine, and GM-CSF in stage IV melanoma [Abstract]. J Clin Oncol, 29(suppl), 8546.
- K F Grossmann, J H Ward, W L Akerley, M J Glantz, J F De Groot, R Aiken, J J Olson, Y Matsuoka, M K Yu, R L Jensen, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, Huntsman Cancer Institute, University of UtahHuntsman Cancer Institute-Intermountain Cancer Care Program, Salt Lake City, UT, Penn State Hershey Medical Center, Hershey, PA, University of Texas M D Anderson Cancer Center, Houston, TX, Mount Sinai School of Medicine, New York, NY, Emory University, Atlanta, GA, Myriad Pharmaceuticals, Inc, Salt Lake City, UT (). A clinical study investigating MPC-6827 with carboplatin in the treatment of patients with relapsed glioblastoma multiforme [Abstract]. J Clin Oncol, 28(15s), 2095.
- J H Schiller, W L Akerley, W Brugger, D Ferrari, E G Garmey, D E Gerber, S V Orlov, R Ramlau, J Von Pawel, L V Sequist, University of Texas Southwestern Medical Center, Dallas, TX, Huntsman Cancer Institute, University of UtahHuntsman Cancer Institute-Intermountain Cancer Care Program, Salt Lake City, UT, Schwarzwald-Baar Clinic, Villingen-Schwenningen, Germany, Arqule, Inc, Woburn, MA, St Petersburg Pavlov State Medical University, Saint Petersburg, Russia, Wielkopolskie Centrum Chorob Pluc i Gruzlicy, Poznan, Poland, Asklepios Klinikum Gauting, Munich, Germany, Massachusetts General Hospital Cancer Center, Boston, MA (). Results from ARQ 197-209: A global randomized placebo-controlled phase II clinical trial of erlotinib plus ARQ 197 versus erlotinib plus placebo in previously treated EGFR inhibitor-naive patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) [Abstract]. J Clin Oncol, 28(18s), LBA7502.
- K A Margolin, J Moon, L E Flaherty, C D Lao, W L Akerley, J A Sosman, J M Kirkwood, V K Sondak, Southwest Oncology Group, University of Washington, Seattle, WA, Southwest Oncology Group Statistical Center, Seattle, WA, Wayne State University, Detroit, MI, University of Michigan, Ann Arbor, MI, Huntsman Cancer Institute, University of UtahHuntsman Cancer Institute-Intermountain Cancer Care Program, Salt Lake City, UT, Vanderbilt University Medical Center, Nashville, TN, University of Pittsburgh Cancer Institute, Pittsburgh, PA, H Lee Moffitt Cancer Center amp Research Institute, Tampa, FL (). Randomized phase II trial of sorafenib (SO) with temsirolimus (TEM) or tipifarnib (TIPI) in metastatic melanoma: Southwest Oncology Group Trial S0438 [Abstract]. J Clin Oncol, 28(15s), 8502.
- W Hwu, W L Akerley, J Stephenson, M K Yu, B A Evans, G Mather, E A Swabb, O Hamid, M D Anderson Cancer Center, Houston, TX, Huntsman Cancer Institute, University of UtahHuntsman Cancer Institute-Intermountain Cancer Care Program, Salt Lake City, UT, Oncology Research Institute and the Cancer Treatment Center, Greenville, SC, Myriad Pharmaceuticals, Inc, Salt Lake City, UT, The Angeles Clinic and Research Institute, Santa Monica, CA (). Final report: Combination of MPC-6827 with temozolomide for the treatment of patients with metastatic melanoma [Abstract]. J Clin Oncol, 28(15s), 8531.
- Akerley, WL, Rich, NT, Egbert L, Harker WG, Van Duren T, Smit J and Hoffman JM (). Bevacizumab/erlotinib (BEER) as first-line treatment for untreated advanced non-squamous non-small cell lung cancer (NSNSCLC) [Abstract]. J Clin Oncol, 28(15 suppl), 18008.
- Akerley WL, Langer CJ, Oh Y, Strickland DK, et al (). Acceptable safety of bevacizumab therapy in patients with brain metastases due to non-small cell lung cancer [Abstract]. J Clin Oncol, 26(15s), 8043.
- Akerley W, Schabel M, Morell G, et al (). A randomized phase 2 trial of combretatstatin A4 phosphate (CA4P) in combination with paclitaxel and carboplatin to evaluate safety and efficacy in subjects with advanced imageable malignancies [Abstract]. J Clin Oncol, 25 (18s)(616s), 14060.
- Spahr J, Akerley W, Rodgers G, et al (). Cancer survival: Which low molecular weight heparin (LMWH) is best? [Abstract]. J Clin Oncol, 25 (18s)(717s), 19624.
- Kurzrock R, Akerley W, Hong D, et al (). Two phase 1 studies of MPC-6827, a novel vascular disrupting agent (VDA), in patients with advanced solid tumors and CNS metastases [Abstract]. J Clin Oncol, 25 (18s)(163s), 3604.
- Akerley W (). Erlotinib for Untreated Stage IV NSCLC with Good Prognosis [Abstract]. J Clin Oncol, 24(18s), 7178.
- Wheeler RH, Jones D, Sharma P, Davis K, Spilker H, Boucher K, Leachman S, Grossman D, Salzman K, Akerley W (). Clinical and Molecular Phase II Study of Gefitinib in Patients with recurrent Cancer of the Head and Neck [Abstract]. J Clin Oncol, 23(507s), 5531.
- Penson DF, McLerran D, Feng Z, Li L, Akerley W, Albertsen PC, Gilliland F, Hamilton A, Hoffman RM, Stephenson RA, Alonzo T, Potosky AL, Stanford JL (). Five-year Urinary and Sexual Outcomes after Radical Prostatectomy: Results from the Prostate Cancer Outcomes Study [Abstract]. Proc AUA, 1663.
- Akerley W, Wade M, Florell S, Sharma P, Milash B, Buys S, Fitzpatrick F, Wheeler R (). Pharmacodynamic Study of Gefitinib in Skin from Patients with Recurrent Carcinoma of Head + Neck [Abstract]. J Clin Oncol, 23(524s), 5599.
- Akerley W, Maul S, Majer M (). Kinetic Model of Survival for Advanced Non-small Cell Lung Cancer (NSCLC) Predicts Enrichment Bias Affects 2nd Line Treatment Trials [Abstract]. Lung Cancer, 49 suppl 2(S85), PD063.
- Akerley W, Maul S, Majer M, Fitzpatrick F (). Erlotinib for Good Prognosis patients with Untreated Stage IV NSCLC. Lung Cancer [Abstract]. Lung Cancer, 49 suppl 2(S233), P442.
- Fanucchi MP, Fossella FV, Belt R, Natale R, Fidias P, Carbone DP, Govindan R, Raez LE, Robert F, Ribeiro M, Akerley W, et al (). Bortezomib ± docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC): a phase II study [Abstract]. J Clin Oncol, 23(629s), 7034.
- Dibble R, Langeburg W, Bair S, Ward J, Akerley W (). Natural History of Non-small Cell Lung Cancer in Non-smokers [Abstract]. J Clin Oncol, 23(683s), 7252.
- Sikov W, Akerley W (2005). Preliminary Results of a Randomized Study of Three Schedules of Weekly Taxol Induction Therapy in Metastatic Breast Cancer [Abstract]. Proc San Antonio Breast Cancer Meeting, 69(360), 271.
- Penson DF, McLerran D, Feng Z, Li L, Akerley W, Albertsen PC, Gilliland F, Hamilton A, Hoffman RM, Stephenson RA, Alonzo T, Potosky AL, Stanford JL (). Five-year Urinary and Sexual Outcomes After Watchful Waiting: Results from the Prostate Cancer Outcomes Study [Abstract]. Proc AUA, 672.
- Akerley W, McCoy J, Hesketh P, Kaye L, Crowley J, Gandara D (2004). SWOG 0019: A Phase II Study of Gemcitabine and Irinotecan for Patients with Untreated Extensive Stage Small Cell Lung Cancer (SCLC) [Abstract]. Proc ASCO, 22, #7202.
- Kim D, Shyr Y, Akerley W, Choy H (2003). Tumor Responsiveness To Combined Modality Therapy (CMT) Is Highly Significant Predictor of Survival For Patients With Locally Advanced Non-Small Cell Lung Cancer (LANSCLC) [Abstract]. Lung Cancer, 41 (S2), 239 #588.
- Kim D, Akerley W, Shyr Y, Choy H (2003). Combined Modalitly Therapy (CMT) Using Concurrent Radiation Therapy (RT) With Paclitaxel Based Chemotherapeutic Regimen In Locally Advanced Non-Small Cell Lung Cancer (LANSCLC): Long Term Follow Up and Analysis of Long Term Survivors [Abstract]. Lung Cancer, 41 (S2), 240 #589.
- Choy H, Kim DW, Akerley W, Safran H, Shyr Y, Turrisi AT, Graziano S, Kennedy T, Johnson DH (2003). Combined Modality Therapy Using Concurrent Radiation with Paclitaxel-based Chemotherapy in Unresectable Locally Advanced NSCLC: Long term follow-up of 3 Sequential Multi-Institutional Trials [Abstract]. Proc ASCO, 21, #2464.
- Sikov W, Akerley W, Kahanic S, Mangalik A, Arun B, Houston GA, Perry M, Bertoli L, Kugler J (2002). Multicenter, 3-Arm Randomized Study of High-Dose Weekly Paclitaxel Versus Standard-Dose Weekly Paclitaxel for Metastatic Breast Cancer [Abstract]. Proc ASCO, 21, 34a, #134.
- Makarovskiy A, Siryaporn E, Akerley W (2001). Effect of Taxotere on Aggressive Prostate Cancer Cells in Vitro [Abstract]. Proc AACR, 61(7):#1237.
- Kelly K, Giarritta S, Hayes S, Akerley W, Hesketh P, Wozniak A, Albain K, Crowley J, Gandara D (2001). Should Older Patients Receive Combination Chemotherapy for Advanced Stage NSCLC: An Analysis of SWOG Trials 9509 and 9308 [Abstract]. Proc ASCO, 20, 329a #1313.
- Akerley W, Coldman A (2001). Two Compartment Model of Survival in Advanced Non-small Cell Lung Cancer [Abstract]. Proc ASCO, 20, 340a #1356.
- Wanebo H, Chougule P, Ready N, Safran H, Akerley W, et al (2001). Preoperative Chemotherapy with Paclitaxel and Carboplatin and Radiation Achieves High Rates of Local Regional Control but Continued Erosion of Survival by Distant Disease [Abstract]. Proc ASCO, 20, 235a #937.
- Akerley W (2001). Current Topics and Future Perspective in Lung Cancer [Abstract]. J Japanese Respiratory Society, 39 (3 Suppl 2), 97.
- Ives C, Akerley W, Safran H, Reddy N, Mega T, Kennedy T, Zaner K (2001). Weekly Gemcitabine and Paclitaxel for Advanced Stage NSCLC: A Multi-Institutional Trial [Abstract]. Proc ASCO, 20, 280b #2870.
- Choy H, Schumaker D, DeVore R, Akerley W, Johnson D (2000). Role of Paclitaxel in Combined Modality Therapy for Locally Advanced Non-Small Cell Lung Cancer (NSCLC): MultiInstitutional Trials Exploring Sequential Phase II Studies of Paclitaxel +/- Carboplatin and Radiation Therapy (+/- Hyperfractionation) [Abstract]. Lung Cancer, 29 (S1), 106 #349.
- Akerley W, Crowley J, Giroux D, Gandara D (2000). Response to Chemotherapy as a Predictor of Survival in Advanced NSCLC: Review of the SWOG Database [Abstract]. Lung Cancer, 29 (S1), 33 #106.
- Choy H, DeBore R, Akerley W, Safran H, Graziano S, Williams T, Bogart J, Shyr Y, Johnson D (2000). Sequential Phase II Studies of Paclitaxel +/- Carboplatin and Radiation Therapy (+/- Hyperfractionation) for Locally Advanced Non-Small Cell Lung Cancer (NSCLC):Multiinstitutional Trials [Abstract]. Proc ASCO, 19, 499a #1951.
- Akerley W, Herndon J, Turrisi A, Graziano S, Williams T, Sikov W, Watson D, Choy H, Green M (2000). Induction Chemotherapy with Paclitaxel and Carboplatin followed by Concurrent Thoracic Radiation and Weekly PC for Patients with Unresectable Stage III NSCLC: Preliminary Analysis of a Phase II Trial by the Cancer and Leukemia Group B [Abstract]. Proc ASCO, 19, 490a #1915.
- Schumaker D, Choy H, Akerley W, DeVore R, Shyr Y, Hande K, Johnson D (2000). Tumor Volume Decrease is a Predictor of Survival Following Combined Modality Therapy for Stage III Non-Small Cell Lung Cancer:Retrospective Analysis of Mult-Institutional Trials [Abstract]. Proc ASCO, 19, 505a #1977.
- Savarese D, Taplin M, Marchessani B, Kreis W, Akerley W, Godley P, et al (1999). A Phase II Study of Docetaxel, Estramustine, and Low Dose Hydrocortisone in Hormone Refractory Prostate Cancer: Preliminary Results of CALGB 9780 [Abstract]. Proc AUA.
- Wanebo H, Chougule P, Ready N, Safran H, Akerley W, Koness R, McRae R, Nigri P, Leone L, Kennedy T, Webber B (1999). Surgical Resection is Necessary to Maximize Tumor Control In Function Preserving, Aggressive Chemoradiation Protocols for Advanced Squamous Cancer of the Head and Neck (Stage III and IV) [Abstract]. Proc ASCO, 18, 410a #1585.
- King T, Akerley W, Walsh K, Mangray S, and Safran H (1999). Paclitaxel Activity Is Not Decreased in Non-small Cell Lung Cancer wtih p53 Mutations [Abstract]. Proc ASCO, 18, 511a #1973.
- Savarese DM, Taplin ME, Marchesani B, Kreis W, Akerley WL, Godley PA, Halabi S, Vogelsang NJ (1999). A Phase II Study of Docetaxel, Estramustine and Low Dose Hydrocortisone in Hormone Refractory Prostate Cancer [Abstract]. Proc ASCO, 18, 321a #1234.
- Kim P, Akerley W, Safran H, Pryzgoda J, Strenger R, Sikov W, Rege V, Kennedy T and Legare R (1999). Vinorelbine and Estramustine for Previously Treated, Advanced Breast Cancer [Abstract]. Proc ASCO, 18, 133a #509.
- Robinson J, Akerley W, Safran H, Calabresi P, Mega A, Sikov W, Fram R, Kennedy T and Leone L (1999). High-dose Weekly Paclitaxel and Amifostine (as a Neuroprotectant) for Advanced Non-small Cell Lung Cancer [Abstract]. Proc ASCO, 18, 605a #2337.
- Akerley W, Herndon J, Egorin MJ, Lyss A, Kindler H, Savarese D, Sherman CA, Rosen MD, Ratain M and Green MR (1999). CALGB 9731: Phase II Trial of Weekly Paclitaxel for Advanced Non-small Cell Lung Cancer [Abstract]. Proc ASCO, 18, 462a #1783.
- Sikov W, Akerley W, Cummings F, and Strenger R (1999). High Dose Weekly Paclitaxel in Metastatic and Locally Advanced Breast Cancer [Abstract]. Sem Oncol, 26(suppl 2), 33.
- Akerley W, Choy H, Safran H, Graziano S (1998). Paclitaxel-based Concurrent Chemoradiation for Unresectable Non-small Cell Lung [Abstract]. Proc 8th Inter Congress of Anti-Cancer Treatment, S 6.
- Akerley W, Leone L, Safran H, Sikov W, Sambandam S, Josephs P, Kennedy T (1998). Phase I Trial of Weekly Paclitaxel and Carboplatin [Abstract]. Proc ASCO, 17, 235a #904.
- Wanebo H, Chougule P, Akerley W, Koness R, McRae R (1998). Preoperative Chemoradiation Coupled with Aggressive Resection Ensures Near Total Control in Advanced Head and Neck Cancer [Abstract]. Proc SHNS.
- Wehbe T, Akerley W, Nodo R, et al (1998). Strontium-89, Estramustine and Vinblastine (SEV) in Hormone-Refractory Prostate Carcinoma: Concurrent Chemoradiotherapy [Abstract]. Proc ASCO, 17, 348a #1341.
- Sikov W, Akerley W, Cummings F, Safran H, and Strenger R (1998). High Dose Weekly Paclitaxel for Locally Advanced and Metastatic Breast Cancer [Abstract]. Proc ASCO, 17, 112a #432.
- Chougule P, Wanebo H, Akerley W, Koness R, McRae R, Nigri P, Leone L, Safran H, Webber B, and Cole B (1998). Preoperative Paclitaxel, Carboplatin and Radiation in Advanced Head and Neck Cancer Induces a High Rate of Complete Pathologic Response at the Primary Site and a High Rate of Organ Preservation [Abstract]. Proc ASCO, 17, 381a #1468.
- Sikov W, Akerley W, Cummings F, Safran H, and Strenger R (1998). High Dose Weekly Paclitaxel for Locally Advanced and Metastatic Breast Cancer [Abstract]. Proc ASCO, 17, 112a #432.
- Aggarwal L, Akerley W, Wingate P, Leone L (1998). Weekly Paclitaxel - Effect on Platelets in Patients with NSCLC and in Patients with Prostate Cancer and Thrombocytopenia [Abstract]. Proc ASCO, 17, 52a #202.
- Proc ASCO (1998). Predictive and Prognostic Importance of Metalloproteinase and Vascular Endothelial Growth Factor Levels in the Cerebrospinal Fluid of Patients with Primary and Metastatic Central Nervous System Cancers [Abstract]. Yee L, Friedberg M, Glantz M, Cole B, Akerley W, Calabresi P, Recht L, Perides G, 17, 378a #1458.
- Keeping H, Lo S, Zou L, Ehrlich M, Akerley W (1998). Strontium-89 Retention by Human Osteoblasts is Associated With Both Intracellular and Extracellular Matrix Accumulation [Abstract]. Proc Orthopedic Research Society.
- Wehbe T, Akerley W, Stein B, et al (1997). Strontium-89, Estramustine and Vinblastine (SEV) in Hormone-Refractory Prostate Carcinoma: Concurrent Chemoradiotherapy [Abstract]. Proc ASCO, 16, 312 #1110.
- Lo S, Akerley W, Drozdoff V, Dinh Q, Zou L, Ehrlich M, Keeping H (1997). Differential Uptake and Retention of Strontium-89 in Human Osteoblast and Bone Metastatic Prostate Cancer Cell Lines [Abstract]. Proc ASBMR Abstract #F693,.
- Choy H, Akerley W, Safran H Graziano S, Turrisi A, Cole B (1997). Phase II Trial of Weekly Paclitaxel, Carboplatin and Concurrent Radiation for Locally Advanced Non-Small Cell Lung Cancer [Abstract]. Proc ASCO, 16, 456 #1637.
- Sikov W, Akerley W, Cummings F, Safran H, Mega A and Strenger R (1997). Weekly High-Dose Paclitaxel In Locally Advanced and Metastatic Breast Cancer [Abstract]. Proc BCRT, 46(1), 95 #412.
- Sikov W, Akerley W, Cummings F, Safran H, Safran H and Strenger R (1997). High Dose Weekly Paclitaxel for Locally Advanced and Metastatic Breast Cancer [Abstract]. Proc ASCO, 16, 191 #669.
- Akerley W, Choy H, Glantz M, Safran H, Sikov W, Rege V, Sambandam S, Josephs J and Wittels E (1997). Phase II Trial of Weekly Paclitaxel for Advanced Non-Small Cell Lung Cancer [Abstract]. Proc ASCO, 16(#1616), 450 #1616.
- Wanebo H, Chougule P, Akerley W, Koness R, McRae R, Nigri P, Leone L, Safran H, Webber B, and Cole B (1997). Preoperative Paclitaxel, Carboplatin and Radiation in Advanced Head and Neck Cancer Induces a High Rate of Complete Pathologic Response at the Primary Site and a High Rate of Organ Preservation [Abstract]. Proc ASCO, 16, 391 #1397.
- Akerley W, Choy H, Glantz M, Safran H, Sikov W, Rege V, Sambandam S, Josephs J and Wittels E (1997). Weekly Paclitaxel -Marked Activity, Diminished Toxicity and Platelet Stimulating Effect [Abstract]. Lung Cancer, 18(S1), 19-20.
- Choy H, Akerley W, Safran H, Graziano S (1997). Concurrent Weekly Paclitaxel and Radiation Therapy for Locally Advanced NSCLC [Abstract]. Lung Cancer, 18(S1), 70-71.
- Wanebo H, Chougule P, Akerley W, Koness R, McRae R, Nigri P, Leone L, Safran H, Webber B, and Cole B (1997). Preoperative Chemoradiotherapy (Paclitaxel, Carboplatin) Coupled with Aggressive Resection as Needed Ensures Nearly Total Control of Advanced Head and Neck Cancer [Abstract]. Proc SHNS.
- Glantz M, Yee L, Lekos A, Kearns C, Mills P, Kim L, Calabresi P, Hochberg F, Egorin M, Akerley W (1996). Is Intrathecal Chemotherapy Necessary? A Pharmacokinetic and Clinical Study of High-Dose Methotrexate in Patients with Leptomenigeal Carcinomatosis [Abstract]. Proc ASCO, 15, 151.
- Akerley W, Choy H, Glantz M, Rege V, Sambandam S, Yee L, Rodrigues B, Leone L (1996). Weekly Paclitaxel for Metastatic Non-Small Cell Lung Cancer: A Phase I Trial [Abstract]. Proc ASCO, 15, 377.
- Chougule P, Wehbe T, Leone L, Akerley W, Safran H, McRae R, Nigri P, Webber B (1996). Concurrent Taxol, Carboplatin and Radiotherapy in Advanced Head and Neck Cancers: A Phase II Study [Abstract]. Proc ASCO, 15, 317.
- Wehbe T, Glantz M, Choy H, Glantz L, Nabbout E, Akerley W, Mills P, Saris S (1996). Histologic Evidence of A Radiosensitizing Effect of Taxol In Astrocytomas [Abstract]. Proc ASCO, 15, 151.
- Choy H, Akerley W, Safran H, Graziano S, Glantz M, Chung C, Cole B (1996). Phase II Trial of Weekly Paclitaxel and Concurrent Radiation For Locally Advanced Non-Small Cell Lung Cancer [Abstract]. Proc ASCO, 15, 371.
- Glantz M, Rhodes C, Cole B, Glantz L, Mills P, Akerley W (1996). p53 Nuclear Overexpression is a Marker for Increased Survival and Paclitaxel Sensitivity in Patients with Glioblastoma Multiforme [Abstract]. Proc ASCO, 15, 159.
- Choy H, Akerley W, Safran H, Graziano S (1996). Concurrent Paclitaxel, Carboplatin and Radiation with Adjuvant Paclitaxel and Carboplatin For Stage III Non-Small Cell Lung Cancer [Abstract]. Proc ASTRO,.
- Wehbe T, Akerley W, Sloan L, Safran H, Sikov W, Maynard J, Stein B (1996). Strontium-89, Estramustine and Vinblastine (SEV) in Hormone-Refractory Prostate Carcinoma: Concurrent Chemoradiotherapy [Abstract]. Proc ASCO, 15, 261.
- Clark J, Bietz J, Cummings F, Sikov W, Browne M, Akerley W, Wanebo H, Darnowski J (1995). Phase II Study of 5-FU, Leucovorin and AZT in Metastatic Colorectal Cancer [Abstract]. Proc ASCO, 14, 220.
- Akerley W, Choy H, Rege V, Glantz M, Josephs J, Chaquette R, Yee L, and Leone L (1995). A Phase I Trial of Weekly Paclitaxel Administered As a 3-Hour Infusion for Metastatic NSCLC [Abstract]. Proc ASCO, 14, 378.
- Browne M, Kennedy T, Cummings F, Sikov W, Akerley W, Donhower R, Clark J (1995). Phase II Study of Sequential Taxol and Cisplatin for the Treatment of Metastatic Breast Cancer [Abstract]. Proc ASCO, 14, 136.
- Glantz M, Friedberg M, Cole B, Choy H, Wahlberg L, Furie K, Akerley W (1994). Double-Blind Randomized, Placebo-Controlled Trial of Anticonvulsant Prophylaxis in Adults with Newly Diagnosed Brain Metastases [Abstract]. Proc ASCO, 13, 176.
- Glantz M, Walhberg L, Kim L, Akerley W, Mills P, Choy H (1994). Phase I Study of Weekly Taxol and Concurrent Cranial Radiation in Adults with Primary Brain Tumors [Abstract]. Proc ASCO, 13, 183.
- Akerley W, Thomas A, Miller M, Clark J, Glantz M, Sikov W, Leone L (1994). Phase II Trial of Oral Etoposide for Carcinoma of Unknown Primary [Abstract]. Proc ASCO, 13, 406.
- Choy H, Akerley W, Safran H, Browne M, Rege V, Papa A, Glantz M, Capistrano M, Puthawala Y, Soderberg C and Leone L (1994). A Phase I Trial of Concurrent Weekly Taxol Administered as a 3 Hour Infusion and Radiation for Advanced Non-Small Cell Lung Cancer [Abstract]. Proc ASCO, 13, 360.
- Sikov W, Akerley W, Browne M, Rosmarin A (1994). Dose Escalation of Carboplatin with Cisplatin and Etoposide with Filgastrin (G-CSF) For Advanced Non-Small Cell Lung Cancer [Abstract]. Proc ASCO, 13, 341.
- Akerley W, Slapak C, Clark J, Cummings F, Posner M (1991). A Phase II Trial of Continuous Infusion Cis-platinum and 5-Fluorouracil with Calcium Leucovorin in Colorectal Carcinoma [Abstract]. Proc ASCO, 10, 152.
- Akerley W, Guyre P, Davis B (1989). Activation of Neutrophil Oxidative Burst Through Types II and III IgG Fc Receptors [Abstract]. Blood, 74(7), Supplement 1, 992a.
- Akerley W, Moritz T, Ryan L, Zacharski L (1989). Effect of Race and Socioeconomic Status on Survival in VA Hospital Patients with Lung and Colon Cancer [Abstract]. Proc ASCO, 8, 97.
- Akerley W, Moritz T, Zacharski L (1989). Comparison of Black and White VA Hospital Patients With Small Cell Cancer of the Lung [Abstract]. Proc ASCO, 8, 238.
- Davis B, Dewhirst P, Akerley W (1988). Neutrophil Oxidative Burst and Stimulated Fluid Pinocytosis Are Activated in Parallel [Abstract]. Cytometry 2, Supplement 1, 57.
- Akerley W, Guyre P, Davis B (1988). Direct Activation of Neutrophil Oxidative Burst By Anti-Fc Receptor Type 1 Monoclonal Antibody [Abstract]. Blood, 70(5), Supplement 1, 140a.
- Grunberg S, Ehler E, McDermed J, Akerley W (1986). Phase I Study of an Extended Regimen of Oral Metaclopramide [Abstract]. Proc ASCO, 5, 261.
- Grunberg S, Akerley W, Baker C, et al (1985). Comparison of Metaclopramide and Dexamethasone in Complete Prevention of Cis-Platinum Induced Vomiting [Abstract]. Proc ASCO, 4, 262.
Newspaper
- Dr Wallace Akerley (). Recognition for Providing Exceptional Patient Care. University of Utah School of Medicine Dept of Internal Medicine Newletter, p. 1.
Other
- Dr Wallace Akerley (). Options in Seconds: Online tool identified clinical trials quickly for cancer patients. University of Utah Health Care Frontiers Magazine (Autumn 2014, p. 7). Salt Lake City: University of Utah Health Care.
- Sobin LH, Wittekind CH, Akerley W (2001). TNM-Mobile, Second Edition (Palm-based Software for TNM: Classification of Malignante Tumours. Wiley Publishers.
Video/Film/CD/Web/Podcast
- Sobin LH, Wittekind CH, Akerley W (2001). TNM-Mobile Edition (Palm-based Software for TNM: Classificatino of Malignante Tumours, Fifth Edition [Video]. New York 2001: Wiley Publishers.
- Perez E, Akerley W, Spriggs D, Pienta K, Thomas M (1999). Weekly Taxol Injection: Enhanced Therapeutic Index in the Treatment of Breast, Lung, Ovarian and Prostate Carcinoma [Video]. Monograph - Bristol Myers Squibb Co..
- Akerley W, Rakatansky H, Scott HD, Star J (August 1997). Ask the Doctor [Web]. Hearst Publishing Internet Site. Available: http://homearts.com/depts/health.
- Akerley W, Ward P, Berard C (1997). Paclitaxel: Alternative Treatment Schedules in Therapeutic Updates in Oncology [Video]. Audio Tape American Oncology Resources, INC..
- Akerley W, Chougule P, Dunphy F, Shin D (1997). Treatment of Head and Neck Cancer - A Clinical Update [Video]. Monograph Moderator: Hainsworth J. Bristol Myers Squibb Co..